



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁷ : C12N 15/63, 15/11, 15/80	A2	(11) International Publication Number: WO 00/56900 (43) International Publication Date: 28 September 2000 (28.09.00)
---	----	---

(21) International Application Number: PCT/US00/07815

(22) International Filing Date: 22 March 2000 (22.03.00)

(30) Priority Data:
09/274,449 22 March 1999 (22.03.99) US(71) Applicant: NOVO NORDISK BIOTECH, INC. [US/US]; 1445
Drew Avenue, Davis, CA 95616-4880 (US).(72) Inventors: BERKA, Randy, M.; 3609 Modoc, Davis, CA
95616 (US). REY, Michael, W.; 605 Robin Place, Davis,
CA 95616 (US). BROWN, Kimberly; 8322 Windswept
Court, Elk Grove, CA 95758 (US). BROWN, Stephen, H.;
3708 Miwok Place, Davis, CA 95616 (US).(74) Agents: ZELSON, Steve, T. et al.; Novo Nordisk of North
America, Inc., Suite 6400, 405 Lexington Avenue, New
York, NY 10174 (US).(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG,
BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS,
MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GW, ML, MR, NE, SN, TD, TG).**Published***Without international search report and to be republished
upon receipt of that report.*

(54) Title: PROMOTERS FOR EXPRESSING GENES IN A FUNGAL CELL



(57) Abstract

The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first nucleic acid sequence encoding the polypeptide operably linked to a second nucleic acid sequence comprising a promoter foreign to the nucleic acid sequence, wherein the promoter comprises a sequence selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3, and a subsequence thereof; and mutant, hybrid, and tandem promoters thereof; and (b) isolating the polypeptide from the cultivation medium. The present invention also relates to the isolated promoter sequences and to constructs, vectors, and fungal host cells comprising the promoter sequences operably linked to nucleic acid sequences encoding polypeptides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROMOTERS FOR EXPRESSING GENES IN A FUNGAL CELL

Background of the Invention

5

Field of the Invention

The present invention relates to methods for producing polypeptides. The present invention also relates to isolated promoters and to nucleic acid constructs, vectors, and host cells comprising the promoters operably linked to nucleic acid sequences encoding polypeptides.

10

Description of the Related Art

The recombinant production of a heterologous protein in a fungal host cell, particularly a filamentous fungal cell such as *Aspergillus*, may provide for a more desirable vehicle for producing the protein in commercially relevant quantities.

15

Recombinant production of a heterologous protein is accomplished by constructing an expression cassette in which the DNA coding for the protein is placed under the expression control of a promoter, excised from a regulated gene, suitable for the host cell. The expression cassette is introduced into the host cell, usually by plasmid-mediated transformation. Production of the heterologous protein is then achieved by culturing the transformed host cell under inducing conditions necessary for the proper functioning of the promoter contained on the expression cassette.

20

The development of a new fungal host cell for the recombinant production of proteins generally requires the availability of promoters that are suitable for controlling the expression of the proteins in the host cell. *Fusarium venenatum* has been shown to be useful as a new host cell for such expression (WO 96/00787, WO 97/26330). Moreover, the promoter from the *Fusarium oxysporum* trypsin-like protease gene has been described which is useful for expressing heterologous genes in *Fusarium venenatum* host cells (US 5,837,847).

25

However, there is a need in the art for new promoters for controlling the expression of heterologous genes.

30

It is an object of the present invention to provide improved methods for producing a polypeptide in a fungal host cell and new promoters for such production.

Summary of the Invention

The present invention relates to methods for producing a polypeptide, comprising:

5 (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first nucleic acid sequence encoding the polypeptide operably linked to a second nucleic acid sequence comprising a promoter foreign to the nucleic acid sequence, wherein the promoter comprises a sequence selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1,

10 nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3; and subsequences thereof; and mutant, hybrid, and tandem promoters thereof; and (b) isolating the polypeptide from the cultivation medium.

The present invention also relates to isolated promoters sequences and to constructs, vectors, and fungal host cells comprising one or more of the promoters

15 operably linked to a nucleic acid sequence encoding a polypeptide.

The present invention also relates to methods for obtaining mutant promoters of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3.

The present invention also relates to isolated nucleic acid sequences, selected

20 from the group consisting of:

(a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 65% identity with amino acids 22 to 581 of SEQ ID NO. 4, at least 65% identity with amino acids 19 to 200 of SEQ ID NO. 5, or at least 65% identity with amino acids 1 to 187 of SEQ ID NO. 6;

25 (b) a nucleic acid sequence having at least 65% homology with nucleotides 4013 to 5743 of SEQ ID NO. 1, at least 65% homology with nucleotides 993 to 1593 of SEQ ID NO. 2, or at least 65% homology with nucleotides 3061 to 3678 of SEQ ID NO. 3;

(c) a nucleic acid sequence which hybridizes under very low, low, medium,

30 medium-high, high, or very high stringency conditions with (i) nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3; (ii) the cDNA sequence contained in nucleotides 4013 to 5743 of

SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3; (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii);

(d) a nucleic acid sequence encoding a variant of the polypeptide having an amino acid sequence of SEQ ID NO. 4, SEQ ID. NO. 5, or SEQ ID NO. 6 comprising a substitution, deletion, and/or insertion of one or more amino acids;

(e) an allelic variant of (a), (b), or (c); and

(f) a subsequence of (a), (b), (c), or (e).

The present invention further relates to constructs, vectors, and recombinant host cells of the nucleic acid sequences.

Brief Description of the Figures

Figures 1A-F shows the genomic DNA sequence and the deduced amino acid sequence of a *Fusarium venenatum* glucoamylase gene (SEQ ID NOs. 1 and 4, respectively).

Figures 2A-C shows the genomic DNA sequence and the deduced amino acid sequence of a *Fusarium venenatum* gene designated "Daria" (SEQ ID NOs. 2 and 5, respectively).

Figures 3A-D shows the genomic DNA sequence and the deduced amino acid sequence of a *Fusarium venenatum* gene designated "Quinn" (SEQ ID NOs. 3 and 6, respectively).

Figure 4 shows a restriction map of pDM181.

Figure 5 shows a restriction map of pSheB1.

Figure 6 shows a restriction map of pDM194.

Figure 7 shows a restriction map of pJRoy35.

Figure 8 shows a restriction map of pDM218.

Figure 9 shows a restriction map of pEJG25A.

Figure 10 shows a restriction map of pMWR60.

Figure 11 shows a restriction map of pRaMB62.

Figure 12 shows a restriction map of pRaMB64.

Figure 13 shows a restriction map of pRaMB66.

Figure 14 shows comparative expression of a *Humicola lanuginosa* lipase reporter gene in *Fusarium venenatum* under control of *Fusarium venenatum* amyloglucosidase (pAMG) and *Fusarium oxysporum* trypsin (pSP387) promoters.

5

Detailed Description of the Invention

The present invention relates to methods for producing a polypeptide, comprising (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first nucleic acid sequence encoding the polypeptide operably linked to a second nucleic acid sequence comprising a promoter foreign to the first nucleic acid sequence, wherein the promoter comprises a sequence selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3, and subsequences thereof; and mutant, hybrid, and tandem promoters thereof; and (b) isolating the polypeptide from the cultivation medium.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate.

The resulting polypeptide may be recovered by methods known in the art. For

example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptides may be purified by a variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing), differential solubility (*e.g.*, ammonium sulfate precipitation), SDS-PAGE, or extraction (see, *e.g.*, *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

Promoters

The term "promoter" is defined herein as a DNA sequence that binds RNA polymerase and directs the polymerase to the correct downstream transcriptional start site of a nucleic acid sequence encoding a polypeptide to initiate transcription. RNA polymerase effectively catalyzes the assembly of messenger RNA complementary to the appropriate DNA strand of the coding region. The term "promoter" will also be understood to include the 5' non-coding region (between promoter and translation start) for translation after transcription into mRNA, *cis*-acting transcription control elements such as enhancers, and other nucleotide sequences capable of interacting with transcription factors.

The term "mutant promoter" is defined herein as a promoter having a nucleotide sequence comprising a substitution, deletion, and/or insertion of one or more nucleotides of a parent promoter, wherein the mutant promoter has more or less promoter activity than the corresponding parent promoter. The term "mutant promoter" will also encompass natural variants and *in vitro* generated variants obtained using methods well known in the art such as classical mutagenesis, site-directed mutagenesis, and DNA shuffling.

The term "hybrid promoter" is defined herein as parts of two more promoters that are fused together to generate a sequence that is a fusion of the two or more promoters, which is operably linked to a coding sequence and mediates the transcription of the coding sequence into mRNA.

The term "tandem promoter" is defined herein as two or more promoter sequences

each of which is operably linked to a coding sequence and mediates the transcription of the coding sequence into mRNA.

The term "operably linked" is defined herein as a configuration in which a control sequence, *e.g.*, a promoter sequence, is appropriately placed at a position relative to a coding sequence such that the control sequence directs the production of a polypeptide encoded by the coding sequence.

The term "coding sequence" is defined herein as a nucleic acid sequence that is transcribed into mRNA which is translated into a polypeptide when placed under the control of the appropriate control sequences. The boundaries of the coding sequence are generally determined by the ATG start codon located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, genomic DNA, cDNA, semisynthetic, synthetic, and recombinant nucleic acid sequences.

In a preferred embodiment, the promoter has the nucleic acid sequence of nucleotides 1 to 3949 of SEQ ID NO. 1, or a subsequence thereof. The subsequence preferably contains at least about 2100 nucleotides, more preferably at least about 2400 nucleotides, and most preferably at least about 2700 nucleotides.

In another preferred embodiment, the promoter has the nucleic acid sequence of nucleotides 1 to 938 of SEQ ID NO. 2, or a subsequence thereof. The subsequence preferably contains at least about 840 nucleotides, more preferably at least about 870 nucleotides, and most preferably at least about 900 nucleotides.

In another preferred embodiment, the promoter has the nucleic acid sequence of nucleotides 1 to 3060 of SEQ ID NO. 3, or a subsequence thereof. The subsequence preferably contains at least about 2100 nucleotides, more preferably at least about 2400 nucleotides, and most preferably at least about 2700 nucleotides.

In another preferred embodiment, the promoter is the nucleic acid sequence contained in plasmid pECO3 which is contained in *Escherichia coli* NRRL B-30067. In another preferred embodiment, the promoter is the nucleic acid sequence contained in plasmid pFAMG which is contained in *Escherichia coli* NRRL B-30071. In another preferred embodiment, the promoter is the nucleic acid contained in plasmid pQUINN which is contained in *Escherichia coli* NRRL B-30075.

In the methods of the present invention, the promoter may also be a mutant of the promoters described above having a substitution, deletion, and/or insertion of one or more nucleotides in the nucleic acid sequence of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, or nucleotides 1 to 3060 of SEQ ID NO. 3.

5 A mutant promoter may have one or more mutations. Each mutation is an independent substitution, deletion, and/or insertion of a nucleotide. The introduction of a substitution, deletion, and/or insertion of a nucleotide into the promoter may be accomplished using any of the methods known in the art such as classical mutagenesis, site-directed mutagenesis, or DNA shuffling. Particularly useful is a procedure which
10 utilizes a supercoiled, double stranded DNA vector with an insert of interest and two synthetic primers containing the desired mutation. The oligonucleotide primers, each complementary to opposite strands of the vector, extend during temperature cycling by means of *Pfu* DNA polymerase. On incorporation of the primers, a mutated plasmid containing staggered nicks is generated. Following temperature cycling, the product is
15 treated with *DpnI* which is specific for methylated and hemimethylated DNA to digest the parental DNA template and to select for mutation-containing synthesized DNA. Other procedures known in the art may also be used.

In a preferred embodiment, the promoter is a mutant of nucleotides 1 to 3949 of SEQ ID NO. 1. In another preferred embodiment, the promoter is a mutant of
20 nucleotides 1 to 938 of SEQ ID NO. 2. In another preferred embodiment, the promoter is a mutant of nucleotides 1 to 3060 of SEQ ID NO. 3.

In the methods of the present invention, the promoter may also be a hybrid promoter comprising a portion of one or more promoters of the present invention; a portion of a promoter of the present invention and a portion of another promoter, *e.g.*, a
25 leader sequence of one promoter and the transcription start site from the other promoter; or a portion of one or more promoters of the present invention and a portion of one or more other promoters. The other promoter may be any promoter sequence which shows transcriptional activity in the fungal host cell of choice including a mutant, truncated, and hybrid promoter, and may be obtained from genes encoding extracellular or intracellular
30 polypeptides either homologous or heterologous to the host cell. The other promoter sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide and native or foreign to the cell.

Examples of other promoters useful in the construction of hybrid promoters with the promoters of the present invention include the promoters obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, and *Fusarium oxysporum* trypsin-like protease (WO 96/00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase), *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* galactokinase (GAL1), *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP), and *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, and mutant, truncated, and hybrid promoters thereof. Other useful promoters for yeast host cells are described by Romanos *et al.*, 1992, *Yeast* 8: 423-488.

The promoter may also be a tandem promoter comprising two more promoters of the present invention or alternatively one or more promoters of the present invention and one or more other promoters, such as those exemplified above. The two or more promoter sequences of the tandem promoter may simultaneously promote the transcription of the nucleic acid sequence. Alternatively, one or more of the promoter sequences of the tandem promoter may promote the transcription of the nucleic acid sequence at different stages of growth of the cell.

In the methods of the present invention, the promoter is foreign to the nucleic acid sequence encoding a polypeptide of interest, but the promoter or nucleic acid sequence may be native to the fungal host cell. A mutant, hybrid, or tandem promoter of the present invention will be understood to be foreign to a nucleic acid sequence encoding a polypeptide even if the wild-type promoter is native to the nucleic acid sequence.

A mutant, hybrid, or tandem promoter of the present invention has at least about 20%, preferably at least about 40%, more preferably at least about 60%, more preferably at least about 80%, more preferably at least about 90%, more preferably at least about 100%, even more preferably at least about 200%, most preferably at least about 300%, and even most preferably at least about 400% of the promoter activity of the promoter of

nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, or nucleotides 1 to 3060 of SEQ ID NO. 3.

Polypeptide Encoding Nucleic Acid Sequences

5 The polypeptide encoded by the nucleic acid sequence may be native or heterologous to the fungal host cell of interest.

 The term "polypeptide" is not meant herein to refer to a specific length of the encoded product and, therefore, encompasses peptides, oligopeptides, and proteins. The term "heterologous polypeptide" is defined herein as a polypeptide which is not native to
10 the fungal cell, a native polypeptide in which modifications have been made to alter the native sequence, or a native polypeptide whose expression is quantitatively altered as a result of a manipulation of the fungal cell by recombinant DNA techniques. For example, a native polypeptide may be recombinantly produced by, *e.g.*, placing a gene encoding the polypeptide under the control of a promoter of the present invention to
15 enhance expression of the polypeptide, to expedite export of a native polypeptide of interest outside the cell by use of a signal sequence, and to increase the copy number of a gene encoding the polypeptide normally produced by the cell. The fungal cell may contain one or more copies of the nucleic acid sequence encoding the polypeptide.

 Preferably, the polypeptide is a hormone or variant thereof, enzyme, receptor or
20 portion thereof, antibody or portion thereof, or reporter. In a preferred embodiment, the polypeptide is secreted extracellularly. In a more preferred embodiment, the polypeptide is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase. In an even more preferred embodiment, the polypeptide is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin
25 glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.

30 The nucleic acid sequence encoding a polypeptide of interest may be obtained from any prokaryotic, eukaryotic, or other source. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean

that the polypeptide is produced by the source or by a cell in which a gene from the source has been inserted.

The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide of interest are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequence from such genomic DNA can be effected, *e.g.*, by using the well known polymerase chain reaction (PCR). See, for example, Innis *et al.*, 1990, *PCR Protocols: A Guide to Methods and Application*, Academic Press, New York. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into the mutant fungal cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

In the methods of the present invention, the polypeptide may also include a fused or hybrid polypeptide in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding one polypeptide to a nucleic acid sequence (or a portion thereof) encoding another polypeptide. Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the polypeptides so that they are in frame and expression of the fused polypeptide is under control of the same promoter(s) and terminator. The hybrid polypeptide may comprise a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides wherein one or more may be heterologous to the mutant fungal cell.

Nucleic Acid Constructs

The present invention also relates nucleic acid constructs comprising a nucleic acid sequence encoding a polypeptide operably linked to a promoter of the present invention and one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the

polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid combined and juxtaposed in a manner that would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains a coding sequence and all the control sequences required for expression of the coding sequence.

An isolated nucleic acid sequence encoding a polypeptide may be further manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing recombinant DNA methods are well known in the art.

In the methods of the present invention, the nucleic acid sequence may comprise one or more native control sequences or one or more of the native control sequences may be replaced with one or more control sequences foreign to the nucleic acid sequence for improving expression of the coding sequence in a host cell.

The term "control sequences" is defined herein to include all components which are necessary or advantageous for the expression of a polypeptide of the present invention. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter of the present invention, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter of the present invention, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.

The control sequence may be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present

invention.

Preferred terminators for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and
5 *Fusarium oxysporum* trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), and *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos *et al.*, 1992, *supra*.

10 The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.

15 Preferred leaders for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, *Saccharomyces cerevisiae* alpha-factor, and *Saccharomyces*
20 *cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to
25 transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Fusarium oxysporum* trypsin-
30 like protease, and *Aspergillus niger* alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Molecular Cellular Biology* 15: 5983-5990.

The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the polypeptide. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* neutral amylase, *Aspergillus niger* glucoamylase, *Rhizomucor miehei* aspartic proteinase, *Humicola insolens* cellulase, and *Humicola lanuginosa* lipase.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding regions are described by Romanos *et al.*, 1992, *supra*.

The control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the genes for *Bacillus subtilis* alkaline protease (*aprE*), *Bacillus subtilis* neutral protease (*nprT*), *Saccharomyces cerevisiae* alpha-factor, *Rhizomucor miehei* aspartic proteinase, and *Myceliophthora thermophila* laccase (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of

the propeptide region.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the *lac*, *tac*, and *trp* operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be operably linked with the regulatory sequence.

The present invention also relates to nucleic acid constructs for altering the expression of a gene encoding a polypeptide which is endogenous to a host cell. The constructs may contain the minimal number of components necessary for altering expression of the endogenous gene. In one embodiment, the nucleic acid constructs preferably contain (a) a targeting sequence, (b) a promoter of the present invention, (c) an exon, and (d) a splice-donor site. Upon introduction of the nucleic acid construct into a cell, the construct inserts by homologous recombination into the cellular genome at the endogenous gene site. The targeting sequence directs the integration of elements (a)-(d) into the endogenous gene such that elements (b)-(d) are operably linked to the endogenous gene. In another embodiment, the nucleic acid constructs contain (a) a targeting sequence, (b) a promoter of the present invention, (c) an exon, (d) a splice-donor site, (e) an intron, and (f) a splice-acceptor site, wherein the targeting sequence directs the integration of elements (a)-(f) such that elements (b)-(f) are operably linked to the endogenous gene. However, the constructs may contain additional components such as a selectable marker.

In both embodiments, the introduction of these components results in production of a new transcription unit in which expression of the endogenous gene is altered. In essence, the new transcription unit is a fusion product of the sequences introduced by the

targeting constructs and the endogenous gene. In one embodiment in which the endogenous gene is altered, the gene is activated. In this embodiment, homologous recombination is used to replace, disrupt, or disable the regulatory region normally associated with the endogenous gene of a parent cell through the insertion of a regulatory sequence which causes the gene to be expressed at higher levels than evident in the corresponding parent cell. The activated gene can be further amplified by the inclusion of an amplifiable selectable marker gene in the construct using methods well known in the art (see, for example, U.S. Patent No. 5,641,670). In another embodiment in which the endogenous gene is altered, expression of the gene is reduced.

10 The targeting sequence can be within the endogenous gene, immediately adjacent to the gene, within an upstream gene, or upstream of and at a distance from the endogenous gene. One or more targeting sequences can be used. For example, a circular plasmid or DNA fragment preferably employs a single targeting sequence, while a linear plasmid or DNA fragment preferably employs two targeting sequences.

15 The constructs further contain one or more exons of the endogenous gene. An exon is defined as a DNA sequence which is copied into RNA and is present in a mature mRNA molecule such that the exon sequence is in-frame with the coding region of the endogenous gene. The exons can, optionally, contain DNA which encodes one or more amino acids and/or partially encodes an amino acid. Alternatively, the exon contains
20 DNA which corresponds to a 5' non-encoding region. Where the exogenous exon or exons encode one or more amino acids and/or a portion of an amino acid, the nucleic acid construct is designed such that, upon transcription and splicing, the reading frame is in-frame with the coding region of the endogenous gene so that the appropriate reading frame of the portion of the mRNA derived from the second exon is unchanged.

25 The splice-donor site of the constructs directs the splicing of one exon to another exon. Typically, the first exon lies 5' of the second exon, and the splice-donor site overlapping and flanking the first exon on its 3' side recognizes a splice-acceptor site flanking the second exon on the 5' side of the second exon. A splice-acceptor site, like a splice-donor site, is a sequence which directs the splicing of one exon to another exon.
30 Acting in conjunction with a splice-donor site, the splicing apparatus uses a splice-acceptor site to effect the removal of an intron.

The present invention further relates to methods for producing a polypeptide

comprising (a) cultivating a homologously recombinant cell, having incorporated therein a new transcription unit comprising a promoter of the present invention, an exon, and/or a splice donor site operably linked to a second exon of an endogenous nucleic acid sequence encoding the polypeptide, under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide. The methods are based on the use of gene activation technology, for example, as described in U.S. Patent No. 5,641,670.

Expression Vectors

The present invention also relates to recombinant expression vectors comprising a promoter of the present invention, a nucleic acid sequence encoding a polypeptide, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the promoter and/or nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the promoter and/or sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with a promoter of the present invention and one or more appropriate control sequences for expression.

The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or

plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene
5 the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB*
10 (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), *trpC* (anthranilate synthase), as well as equivalents thereof. Preferred for use in an *Aspergillus* cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygroscopicus*.

15 The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.

For integration into the host cell genome, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable
20 integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of
25 integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is
30 homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-

homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1433).

More than one copy of a nucleic acid sequence encoding a polypeptide may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook *et al.*, 1989, *supra*).

Host Cells

The present invention also relates to recombinant host cells, comprising a promoter of the present invention operably linked to a nucleic acid sequence encoding a polypeptide, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a promoter of the present invention operably linked to a nucleic acid sequence encoding a polypeptide is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be any fungal cell useful in the methods of the present

invention. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth *et al.*, In, *Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth *et al.*, 1995, *supra*,
5 page 171) and all mitosporic fungi (Hawksworth *et al.*, 1995, *supra*).

In a preferred embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporeogenous yeast (Endomycetales), basidiosporeogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as
10 described in *Biology and Activities of Yeast* (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, *Soc. App. Bacteriol. Symposium Series No. 9*, 1980).

In a more preferred embodiment, the yeast host cell is a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

In a most preferred embodiment, the yeast host cell is a *Saccharomyces*
15 *carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* cell. In another most preferred embodiment, the yeast host cell is a *Kluyveromyces lactis* cell. In another most preferred embodiment, the yeast host cell is a *Yarrowia lipolytica* cell.

20 In another preferred embodiment, the fungal host cell is a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and
25 carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

In a more preferred embodiment, the filamentous fungal host cell is a cell of a species of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*,
30 *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma*.

In a most preferred embodiment, the filamentous fungal host cell is an *Aspergillus* *awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus*

niger or *Aspergillus oryzae* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*,
5 *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*,
10 *Thielavia terrestris*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cell.

In an even most preferred embodiment, the *Fusarium venenatum* cell is *Fusarium venenatum* A3/5, which was originally deposited as *Fusarium graminearum* ATCC 20334 and recently reclassified as *Fusarium venenatum* by Yoder and Christianson,
15 1998, *Fungal Genetics and Biology* 23: 62-80 and O'Donnell *et al.*, 1998, *Fungal Genetics and Biology* 23: 57-67; as well as taxonomic equivalents of *Fusarium venenatum* regardless of the species name by which they are currently known. In another preferred embodiment, the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* A3/5 or *Fusarium venenatum* ATCC 20334, as disclosed in WO
20 97/26330.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences*
25 *USA* 81: 1470-1474. Suitable methods for transforming *Fusarium* species are described by Malardier *et al.*, 1989, *Gene* 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983,
30 *Journal of Bacteriology* 153: 163; and Hinnen *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920.

Methods For Obtaining Mutant Promoters

The present invention further relates to methods for obtaining a mutant promoter, comprising (a) introducing at least one mutation into the sequence of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, or nucleotides 1 to 3060
5 of SEQ ID NO. 3, wherein the mutant promoter has promoter activity; and (b) isolating the mutant promoter.

The present invention also relates to methods for obtaining a mutant promoter by (a) hybridizing a DNA under very low, low, medium, medium-high, high, or very high stringency conditions with (i) SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, (ii) the
10 cDNA sequence contained in SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii); and (b) isolating the mutant promoter from the DNA. Stringency and wash conditions are defined herein.

The mutant promoter may be isolated using methods known in the art such as
15 restriction enzyme digestion or PCR amplification.

Nucleic Acid Sequences

The present invention also relates to isolated nucleic acid sequences, selected from the group consisting of:

20 (a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 65% identity with amino acids 22 to 581 of SEQ ID NO. 4, at least 65% identity with amino acids 19 to 200 of SEQ ID NO. 5, or at least 65% identity with amino acids 1 to 187 of SEQ ID NO. 6;

(b) a nucleic acid sequence having at least 65% homology with nucleotides
25 4013 to 5743 of SEQ ID NO. 1, at least 65% homology with nucleotides 993 to 1593 of SEQ ID NO. 2, or at least 65% homology with nucleotides 3061 to 3678 of SEQ ID NO. 3;

(c) a nucleic acid sequence which hybridizes under very low, low, medium, medium-high, high, or very high stringency conditions with (i) nucleotides 4013 to 5743
30 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3; (ii) the cDNA sequence contained in nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678

of SEQ ID NO. 3; (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii);

- (d) a nucleic acid sequence encoding a variant of the polypeptide having an amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6 comprising a substitution, deletion, and/or insertion of one or more amino acids;
- (e) an allelic variant of (a), (b), or (c); and
- (f) a subsequence of (a), (b), (c), or (e).

The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

In a first embodiment, the present invention relates to isolated nucleic acid sequences encoding polypeptides having an amino acid sequence which has a degree of identity to amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO. 6 (*i.e.*, the mature polypeptide) of at least about 65%, preferably at least about 70%, more preferably at least about 80%, even more preferably at least about 90%, most preferably at least about 95%, and even most preferably at least about 97% (hereinafter "homologous polypeptides"). In a preferred embodiment, the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO. 6. For purposes of the present invention, the

degree of identity between two amino acid sequences is determined by the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10, and gap length penalty of 10.

5 Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5.

Preferably, the nucleic acid sequences of the present invention encode polypeptides that comprise the amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6; or an allelic variant thereof; or a fragment thereof. In a more preferred

10 embodiment, the nucleic acid sequence of the present invention encodes a polypeptide that comprises the amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6. In another preferred embodiment, the nucleic acid sequence of the present invention encodes a polypeptide that comprises amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO. 6; or an

15 allelic variant thereof; or a fragment thereof. In another preferred embodiment, the nucleic acid sequence of the present invention encodes a polypeptide that comprises amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO. 6. In another preferred embodiment, the nucleic acid sequence of the present invention encodes a polypeptide that consists of the amino

20 acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6; or an allelic variant thereof; or a fragment thereof. In another preferred embodiment, the nucleic acid sequence of the present invention encodes a polypeptide that consists of the amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6. In another preferred embodiment, the nucleic acid sequence of the present invention encodes a polypeptide

25 that consists of amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO. 6; or an allelic variant thereof; or a fragment thereof. In another preferred embodiment, the nucleic acid sequence of the present invention encodes a polypeptide that consists of amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO.

30 6.

The present invention also encompasses nucleic acid sequences which encode a polypeptide having the amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ

ID NO. 6, which differ from SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, respectively, by virtue of the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3 which encode fragments of SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6, respectively.

5 A subsequence is a nucleic acid sequence encompassed by SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, except that one or more nucleotides from the 5' and/or 3' end have been deleted. Preferably, a subsequence of SEQ ID NO. 1 contains at least 1410 nucleotides, more preferably at least 1500 nucleotides, and most preferably at least 1590 nucleotides. Preferably, a subsequence of SEQ ID NO. 2 contains at least 450
10 nucleotides, more preferably at least 480 nucleotides, and most preferably at least 510 nucleotides. Preferably, a subsequence of SEQ ID NO. 3 contains at least 465 nucleotides, more preferably at least 495 nucleotides, and most preferably at least 525 nucleotides. A fragment of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6 is a polypeptide having one or more amino acids deleted from the amino and/or carboxy
15 terminus of this amino acid sequence. Preferably, a fragment of SEQ ID NO. 4 contains at least 470 amino acid residues, more preferably at least 500 amino acid residues, and most preferably at least 530 amino acid residues. Preferably, a fragment of SEQ ID NO. 5 contains at least 150 amino acid residues, more preferably at least 160 amino acid residues, and most preferably at least 170 amino acid residues. Preferably, a fragment of
20 SEQ ID NO. 6 contains at least 155 amino acid residues, more preferably at least 165 amino acid residues, and most preferably at least 175 amino acid residues.

An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be
25 silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. The allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

In a second embodiment, the present invention relates to isolated nucleic acid sequences which have a degree of homology to nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 4013 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID
30 NO. 3 (*i.e.*, mature polypeptide coding region) of at least about 65%, preferably about 70%, preferably about 80%, more preferably about 90%, even more preferably about

95%, and most preferably about 97% homology, which encode an active polypeptide; or allelic variants and subsequences thereof. For purposes of the present invention, the degree of homology between two nucleic acid sequences is determined by the Wilbur-Lipman method (Wilbur and Lipman, 1983, *Proceedings of the National Academy of Science USA* 80: 726-730) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters were Ktuple=3, gap penalty=3, and windows=20.

In a third embodiment, the present invention relates to isolated nucleic acid sequences encoding polypeptides which hybridize under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with a nucleic acid probe which hybridizes under the same conditions with (i) nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3; (ii) the cDNA sequence contained in nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3; (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii) (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York). The subsequence of SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3 may be at least 100 nucleotides or preferably at least 200 nucleotides. Moreover, the subsequence may encode a polypeptide fragment.

The nucleic acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6, or a fragment thereof, may be used to design a nucleic acid probe to identify and clone DNA encoding polypeptides from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 35

nucleotides in length. Longer probes can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with ^{32}P , ^3H , ^{35}S , biotin, or avidin). Such probes are encompassed by the present invention.

5 Thus, a genomic DNA or cDNA library prepared from such other organisms may be screened for DNA which hybridizes with the probes described above and which encodes a polypeptide. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and
10 immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA which is homologous with SEQ ID NO. 1 or a subsequence thereof, the carrier material is used in a Southern blot. For purposes of the present invention, hybridization indicates that the nucleic acid sequence hybridizes to a labeled nucleic acid probe corresponding to the nucleic acid sequence shown in SEQ ID NO. 1, SEQ ID NO.
15 2, or SEQ ID NO. 3, their complementary strands, or subsequences thereof, under very low to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions are detected using X-ray film.

 In a preferred embodiment, the nucleic acid probe is the nucleic acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3. In another preferred embodiment, the
20 nucleic acid probe is a nucleic acid sequence which encodes the polypeptide of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6, or subsequences thereof. In another preferred embodiment, the nucleic acid probe is SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3. In another preferred embodiment, the nucleic acid probe is nucleotides 4013 to 5743 of SEQ ID NO. 1, which encodes a mature polypeptide. In another preferred embodiment,
25 the nucleic acid probe is nucleotides 993 to 5743 of SEQ ID NO. 2, which encodes a mature polypeptide. In another preferred embodiment, the nucleic acid probe is nucleotides 3061 to 3678 of SEQ ID NO. 3, which encodes a mature polypeptide. In another preferred embodiment, the nucleic acid probe is the nucleic acid sequence contained in plasmid pECO3 which is contained in *Escherichia coli* NRRL B-30067. In
30 another preferred embodiment, the nucleic acid probe is the nucleic acid sequence contained in plasmid pFAMG which is contained in *Escherichia coli* NRRL B-30071. In another preferred embodiment, the nucleic acid probe is the nucleic acid sequence

contained in plasmid pQUINN which is contained in *Escherichia coli* NRRL B-30076. In another preferred embodiment, the nucleic acid probe is the mature polypeptide coding region contained in plasmid pECO3 which is contained in *Escherichia coli* NRRL B-30067. In another preferred embodiment, the nucleic acid probe is the mature polypeptide coding region contained in plasmid pFAMG which is contained in *Escherichia coli* NRRL B-30071. In another preferred embodiment, the nucleic acid probe is the mature polypeptide coding region contained in plasmid pQUINN which is contained in *Escherichia coli* NRRL B-30076.

For long probes of at least 100 nucleotides in length, very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures.

For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 2 x SSC, 0.2% SDS preferably at least at 45°C (very low stringency), more preferably at least at 50°C (low stringency), more preferably at least at 55°C (medium stringency), more preferably at least at 60°C (medium-high stringency), even more preferably at least at 65°C (high stringency), and most preferably at least at 70°C (very high stringency).

For short probes which are about 15 nucleotides to about 70 nucleotides in length, stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at 5°C to 10°C below the calculated T_m using the calculation according to Bolton and McCarthy (1962, *Proceedings of the National Academy of Sciences USA* 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

For short probes which are about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T_m .

The present invention also relates to isolated nucleic acid sequences produced by

(a) hybridizing a DNA under very low, low, medium, medium-high, high, or very high stringency conditions with (i) nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3, (ii) the cDNA sequence contained in nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, nucleotides 3061 to 3678 of SEQ ID NO. 3, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii); and (b) isolating the nucleic acid sequence from the DNA. The subsequence is preferably a sequence of at least 100 nucleotides such as a sequence which encodes a polypeptide fragment

10 In a fourth embodiment, the present invention relates to isolated nucleic acid sequences which encode variants of the polypeptide having an amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6 comprising a substitution, deletion, and/or insertion of one or more amino acids.

The amino acid sequences of the variant polypeptides may differ from the amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6, or the mature polypeptides thereof, by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

25 Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser,

Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

5 The nucleic acid sequences of the present invention may be obtained from microorganisms of any genus. For purposes of the present invention, the term "obtained from" is used as defined herein. In a preferred embodiment, the polypeptide encoded by a nucleic acid sequence of the present invention is secreted extracellularly.

10 The nucleic acid sequences may be obtained from a fungal source, and more preferably from a yeast strain such as a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* strain; or more preferably from a filamentous fungal strain such as an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* strain.

15 In a preferred embodiment, the nucleic acid sequences are obtained from a *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* strain.

20 In another preferred embodiment, the nucleic acid sequences are obtained from an *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* strain.

25 In another preferred embodiment, the nucleic acid sequences are obtained from a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, *Fusarium venenatum* strain.

In a more preferred embodiment, the nucleic acid sequences are obtained from *Fusarium venenatum*, and most preferably from *Fusarium venenatum* ATCC 20334, *e.g.*, the nucleic acid sequence set forth in SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3. In another more preferred embodiment, the nucleic acid sequence of SEQ ID NO. 1 is the sequence contained in plasmid pECO3 which is contained in *Escherichia coli* NRRL B-30067. In another more preferred embodiment, the nucleic acid sequence of SEQ ID NO. 2 is the sequence contained in plasmid pFAMG which is contained in *Escherichia coli* NRRL B-30071. In another more preferred embodiment, the nucleic acid sequence of SEQ ID NO. 3 is the sequence contained in plasmid pQUINN which is contained in *Escherichia coli* NRRL B-30076. In another preferred embodiment, the nucleic acid sequence is nucleotides 4013 to 5743 of SEQ ID NO. 1, which encodes a mature polypeptide. In another preferred embodiment, the nucleic acid sequence is nucleotides 993 to 1593 of SEQ ID NO. 2, which encodes a mature polypeptide. In another preferred embodiment, the nucleic acid sequence is nucleotides 3061 to 3678 of SEQ ID NO. 3, which encodes a mature polypeptide.

It will be understood that for the aforementioned species, the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, *e.g.*, anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents.

Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

Furthermore, such nucleic acid sequences may be identified and obtained from other sources including microorganisms isolated from nature (*e.g.*, soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a genomic or cDNA library of another microorganism.

Once a nucleic acid sequence encoding a polypeptide has been detected with the probe(s), the sequence may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

The present invention also relates to mutant nucleic acid sequences comprising at least one mutation in the mature polypeptide coding sequence of SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, in which the mutant nucleic acid sequence encodes a polypeptide which consists of amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO. 6, respectively.

The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide have been described herein.

The present invention also relates to nucleic acid constructs, recombinant vectors, and host cells containing the nucleic acid sequences described above. The same methods may be used as described earlier for their construction.

The present invention further relates to the polypeptides encoded by the nucleic acid sequences described above as well as methods of production of the polypeptides using the methods described herein.

The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

Examples

Chemicals used as buffers and substrates were commercial products of at least reagent grade.

Media and Solutions

COVE trace metals solution was composed per liter of 0.04 g of $\text{NaB}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$, 0.4 g of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 1.2 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.7 g of $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, 0.8 g of $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$, and 10 g of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$.

50X COVE salts solution was composed per liter of 26 g of KCl, 26 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 76 g of KH_2PO_4 , and 50 ml of COVE trace metals.

COVE medium was composed per liter of 342.3 g of sucrose, 20 ml of 50X COVE salt solution, 10 ml of 1 M acetamide, 10 ml of 1.5 M CsCl_2 , and 25 g of Noble agar.

50X Vogels medium was composed per liter of 150 g of sodium citrate, 250 g of

KH₂PO₄, 10 g of MgSO₄·7H₂O, 10 g of CaCl₂·2H₂O, 2.5 ml of biotin stock solution, and 5.0 ml of AMG trace metals solution.

? Trace metals solution was composed per liter of 14.3 g of ZnSO₄·7H₂O, 2.5 g of CuSO₄·5H₂O, 0.5 g of NiCl₂, 13.8 g of FeSO₄, 8.5 g of MnSO₄, and 3.0 g of citric acid.

5 COVE top agarose was composed per liter of 20 ml of 50X COVE salts, 0.8 M sucrose, 1.5 M cesium chloride, 1.0 M acetamide, and 10 g of low melt agarose, pH adjusted to 6.0.

BASTA top agarose was composed of COVE top agarose supplemented with 10 mg/ml of the herbicide Basta™ (Hoechst Schering, Rodovre, Denmark).

10 RA sporulation medium was composed per liter of 50 g of succinic acid, 12.1 g of NaNO₃, 1 g of glucose, 20 ml of 50X Vogels, and 0.5 ml of a 10 mg/ml NaMoO₄ stock solution, pH to 6.0.

YEPG medium was composed per liter of 10 g of yeast extract, 20 g of peptone, and 20 g of glucose.

15 STC was composed of 0.8 M sorbitol, 25 mM Tris pH 8, 25 mM CaCl₂.

SPTC was composed of 40% PEG 4000, 0.8 M sorbitol, 25 mM Tris pH 8, 25 mM CaCl₂.

20 M400Da medium was composed per liter of 50 g of maltodextrin, 2 g of MgSO₄·7H₂O, 2 g of KH₂PO₄, 4 g of citric acid, 8 g of yeast extract, 2 g of urea, and 1 ml of COVE trace metals solution.

Example 1: Production of *Fusarium venenatum* mycelial tissue

25 *Fusarium venenatum* CC1-3, a morphological mutant of *Fusarium* strain ATCC 20334 (Wiebe *et al.*, 1991, *Mycological Research* 95: 1284-1288), was grown in a two-liter lab-scale fermentor using a fed-batch fermentation scheme with NUTRIOSE™ (Roquette Freres, S.A., Beinheim, France) as the carbon source and yeast extract. Ammonium phosphate was provided in the feed. The pH was maintained at 6 to 6.5, and the temperature was kept at 30°C with positive dissolved oxygen.

30 Mycelial samples were harvested at 2, 4, 6, and 8 days post-inoculum and quick-frozen in liquid nitrogen. The samples were stored at -80°C until they were disrupted for RNA extraction.

Example 2: cDNA library construction

Total cellular RNA was extracted from the mycelial samples described in Example 1 according to the method of Timberlake and Barnard (1981, *Cell* 26: 29-37), and the RNA samples were analyzed by Northern hybridization after blotting from 1% formaldehyde-agarose gels (Davis *et al.*, 1986, *Basic Methods in Molecular Biology*, Elsevier Science Publishing Co., Inc., New York). Polyadenylated mRNA fractions were isolated from total RNA with an mRNA Separator Kit™ (Clontech Laboratories, Inc., Palo Alto, CA) according to the manufacturer's instructions. Double-stranded cDNA was synthesized using approximately 5 µg of poly(A)+ mRNA according to the method of Gubler and Hoffman (1983, *Gene* 25: 263-269) except a *NotI*-(dT)18 primer (Pharmacia Biotech, Inc., Piscataway, NJ) was used to initiate first strand synthesis. The cDNA was treated with mung bean nuclease (Boehringer Mannheim Corporation, Indianapolis, IN) and the ends were made blunt with T4 DNA polymerase (New England Biolabs, Beverly, MA).

The cDNA was digested with *NotI*, size selected by agarose gel electrophoresis (ca. 0.7-4.5 kb), and ligated with pZER0-2.1 (Invitrogen, Carlsbad, CA) which had been cleaved with *NotI* plus *EcoRV* and dephosphorylated with calf-intestine alkaline phosphatase (Boehringer Mannheim Corporation, Indianapolis, IN). The ligation mixture was used to transform competent *E. coli* TOP10 cells (Invitrogen, Carlsbad, CA). Transformants were selected on 2YT agar plates (Miller, 1992, *A Short Course in Bacterial Genetics. A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria*, Cold Spring Harbor Press, Cold Spring Harbor, New York) which contained kanamycin at a final concentration of 50 µg/ml.

Two independent directional cDNA libraries were constructed using the plasmid cloning vector pZER0-2.1. Library A was made using mRNA from mycelia harvested at four days, and Library B was constructed with mRNA from the six day time point. Neither cDNA library was amplified in order to examine a representative "snapshot" of the gene expression profile in the cells. Instead the libraries were plated, titered, and independent clones from each were analyzed by DNA sequencing.

Library A (4 day cells) consisted of about 7.5×10^4 independent clones and Library B (6 day cells) consisted of roughly 1.2×10^5 clones. Miniprep DNA was isolated from forty colonies in each library and checked for the presence and size of

cDNA inserts. In this analysis 39 of 40 colonies (97.5%) from Library A contained inserts with sizes ranging from 600 bp to 2200 bp (avg. = 1050 bp). Similarly, 39 of 40 colonies (97.5%) from Library B had inserts with sizes ranging from 800 bp to 3600 bp (avg. = 1380 bp).

5

Example 3: Template preparation and nucleotide sequencing

From each cDNA library described in Example 2, 1192 transformant colonies were picked directly from the transformation plates into 96-well microtiter dishes which contained 200 µl of 2YT broth (Miller, 1992, *supra*) with 50 µg/ml kanamycin. The plates were incubated overnight at 37°C without shaking. After incubation 100 µl of sterile 50% glycerol were added to each well. The transformants were replicated into secondary, deep-dish 96-well microculture plates (Advanced Genetic Technologies Corporation, Gaithersburg, MD) containing 1 ml of Magnificent Broth™ (MacConnell Research, San Diego, CA) supplemented with 50 µg of kanamycin per ml in each well. The primary microtiter plates were stored frozen at -80°C. The secondary deep-dish plates were incubated at 37°C overnight with vigorous agitation (300 rpm) on rotary shaker. To prevent spilling and cross-contamination, and to allow sufficient aeration, each secondary culture plate was covered with a polypropylene pad (Advanced Genetic Technologies Corporation, Gaithersburg, MD) and a plastic microtiter dish cover.

DNA was isolated from each well using the 96-well Miniprep Kit protocol of Advanced Genetic Technologies Corporation (Gaithersburg, MD) as modified by Utterback *et al.* (1995, *Genome Sci. Technol.* 1: 1-8). Single-pass DNA sequencing was done with a Perkin-Elmer Applied Biosystems Model 377 XL Automatic DNA Sequencer (Perkin-Elmer Applied Biosystems, Inc., Foster City, CA) using dye-terminator chemistry (Giesecke *et al.*, 1992, *Journal of Virology Methods* 38: 47-60) and the reverse lac sequencing primer.

Example 4: Analysis of DNA sequence data

Nucleotide sequence data were scrutinized for quality, and samples giving improper spacing less than or equal to 9.2 or ambiguity levels exceeding 3% were discarded or re-run. Vector sequences were trimmed with assistance of FACTURA™ software (Perkin-Elmer Applied Biosystems, Inc., Foster City, CA). In addition,

sequences were truncated at the end of each sample when the number of ambiguous base calls increased. All sequences were compared to each other to construct overlapping contigs using TIGR Assembler software (Sutton, G.G. *et al.*, 1995, *Genome Science and Technology* 1: 9019) to determine multiplicity of various cDNA species represented in each library. Lastly, all sequences were translated in three frames and searched against a non-redundant data base (NRDB) using GeneAssist™ software (Perkin-Elmer Applied Biosystems, Inc., Foster City, CA) with a modified Smith-Waterman algorithm using the BLOSUM 62 matrix with a threshold score of 70. The NRDB was assembled from Genpept, Swiss-Prot, and PIR databases.

Example 5: Identification of glucoamylase cDNA clones

Putative glucoamylase clones were identified by partial sequencing of random cDNA clones using an Applied Biosystems Model 377 XL Automated DNA Sequencer according to the manufacturer's instructions and comparison of the deduced amino acid sequence to the sequences in the NRDB as described in Example 4. From more than 2000 cDNA sequences analyzed, two clones from Library A and nine clones from Library B showed amino acid sequence homology to glucoamylase proteins from other fungi and yeasts. Among several glucoamylase cDNA clones discovered in this manner, one was estimated to be full-length (encoding the complete protein) on the basis of its alignment to the *Neurospora crassa* (Geneseq protein accession number R71034) and *Humicola grisea* (Trembl accession number Q12623) glucoamylase amino acid sequences and the presence of a possible signal peptide, detected using the Signal-P computer program (Nielsen, *et al.*, 1997, *Protein Engineering* 10: 1-6). This clone designated *E. coli* FA0401 containing plasmid pFA0401 was selected for use as a probe to clone the corresponding glucoamylase genomic DNA sequence from *Fusarium venenatum* (see Example 7).

Example 6: Construction a library of *Fusarium venenatum* genomic DNA

Genomic libraries were constructed in λZipLox as specified by the procedure of Berka *et al.* (1998, *Appl. Environ. Microbiol.* 64, 4423-4427). Briefly, *Fusarium venenatum* total cellular DNA was partially digested with *Tsp509I* and size-fractionated on 1% agarose gels. DNA fragments migrating in the size range 3–7 kb were excised

and eluted from the agarose gel slices using Prep-a-Gene reagents (BioRad, Hercules, CA). The eluted DNA fragments were ligated with *Eco*RI-cleaved and dephosphorylated λ ZipLox vector arms (Life Technologies, Gaithersburg, MD), and the ligation mixtures were packaged using commercial packaging extracts (Stratagene, La Jolla, CA). The
5 packaged DNA libraries were plated and amplified on *Escherichia coli* Y1090ZL cells and stored at 4°C using standard methods (Davis, R.W., Botstein, D., and Roth, J.R., 1980, *Advanced Bacterial Genetics, A Manual for Genetic Engineering*, Cold Spring Harbor Press, Cold Spring Harbor, NY).

10 **Example 7: Isolation, nucleotide sequencing and characterization of a genomic DNA segment encoding *Fusarium venenatum* glucoamylase**

Approximately 50,000 plaques from the *Fusarium venenatum* genomic DNA library (Example 6) were screened by hybridization (Davis *et al.*, 1980, *supra*) with a
15 radiolabeled probe fragment comprising the cloned cDNA insert from pFA0401 (Example 5) using high stringency conditions (*i.e.*, hybridization at 45°C in 50% formamide, 5 x SSPE, 0.3% SDS, 200 μ g/ml sheared and denatured salmon sperm DNA; filters washed once in 0.2 X SSPE with 0.1% SDS at 45°C followed by two washes in 0.2 X SSPE with no SDS at the same temperature). Plaques which gave hybridization
20 signals, were purified twice on *E. coli* Y1090ZL cells, and the individual clones were subsequently excised from the λ ZipLox vector as pZL1-derivatives (D'Alessio *et al.*, 1992, *Focus*® 14: 76). DNA sequence analysis revealed that one of these clones, containing a plasmid designated pFAMG, comprised the entire glucoamylase coding region as well as 3.9 kb of 5'-flanking and 0.3 kb of 3'-flanking DNA encompassing the promoter and terminator regions, respectively (see Figure 1).

25 DNA sequencing of the cloned insert in pFAMG was done with an Applied Biosystems Model 377 XL Automated DNA Sequencer using dye-terminator chemistry. Contiguous sequences were generated using a transposon insertion strategy (Primer Island Transposition Kit, Perkin-Elmer/Applied Biosystems, Inc., Foster City, CA), and the glucoamylase genomic clone from pFAMG was sequenced to an average redundancy
30 of 4.2.

By comparing the genomic sequence data to the contig of glucoamylase cDNA sequences, it was determined that the genomic DNA segment encoding *Fusarium*

venenatum glucoamylase contained an open reading frame of 1743 bp interrupted by an intron of 51 bp and encoding a polypeptide of 581 amino acids. The nucleotide sequence (SEQ ID NO. 1) and deduced amino acid sequence (SEQ ID NO. 4) are shown in Figure 1. Using the SignalP program (Nielsen *et al.*, 1997, *Protein Engineering* 10: 1-6), a signal peptide of 21 residues was predicted, and confirmed by amino terminal sequencing of the glucoamylase protein (Example 8). Thus, the mature glucoamylase is composed of 560 amino acids.

A comparative alignment of fungal glucoamylase protein sequences was undertaken using the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5. The alignment showed that the *Fusarium venenatum* glucoamylase shares identity with the following glucoamylases from other fungi (percent identical residues in parentheses): *Neurospora crassa* [Swissprot P14804] (47%), *Aspergillus niger* [Swissprot P04064] (46%), *Humicola grisea* [Trembl Q12623] (44%), *Hormoconis resinae* [Swissprot Q03045] (41%), *Corticium rolfii* [Q12596] (41%), *Schizosaccharomyces pombe* [Trembl O60087] (31%), and *Rhizopus oryzae* [Swissprot P07683] (23%).

Example 8: Amino terminal sequence analysis of *Fusarium venenatum* glucoamylase

The proteins in a sample of *Fusarium venenatum* fermentation broth (Example 1) were separated by 8-16% Tris-glycine SDS-PAGE (Novex, San Diego, CA) and electroblotted onto a PVDF membrane (Novex, San Diego, CA) using 10 mM CAPS (3-[cyclohexylamino]-1-propanesulfonic acid) in 10% methanol, pH=11.0 for 2 hours at 25 volts. The PVDF membrane was stained with 0.1% Commassie Blue R-250 in 40% methanol/1% acetic acid for 20 seconds and destained in 50% ethanol to observe the protein bands.

The major polypeptide species migrating at approximately 65 kDa was excised and subjected to N-terminal sequencing on an Applied Biosystems 476A Protein Sequencer (Perkin Elmer/Applied Biosystems Division, Foster City, CA) with on-line

HPLC and liquid phase trifluoroacetic acid (TFA) delivery. Sequencing reagents were from Perkin Elmer/Applied Biosystems Division. (Foster City, CA). Detection of phenylthiohydantoin-amino acids was accomplished by on-line HPLC using Buffer A containing 3.5% tetrahydrofuran in water with 18 ml of the Premix concentrate (Perkin Elmer/Applied Biosystems Division, Foster City, CA) containing acetic acid, sodium acetate, and sodium hexanesulfonate and Buffer B containing Acetonitrile. Data was collected and analyzed on a Macintosh IIsi using Applied Biosystems 610 Data Analysis Software. Amino acid identifications were performed by visualizing chromatograms against a light source and determined by the operator. The N-terminal analysis yielded a protein sequence of Ser-Pro-Ser-Lys-Asp-Asn-Ser-Leu-Glu-Arg-Phe-Ile-Asp-Lys-Gln-Ala-Asp-Ile-Ser (SEQ ID NO. 4).

Example 9: Identification of abundant cDNA clones encoding an putative vacuolar associated protein and an unknown secreted gene product

Two additional cDNA species were selected based on their relative abundance among the clones present in Libraries A and B (Example 2).

Clone FA0035, containing pFA0035, encoded a primary translation product of 200 amino acids with a possible signal peptide of 18 amino acids that was detected using the Signal-P computer program (Nielsen, *et al.*, 1997, *supra*). Clone FA0035 was represented by approximately 1.9% of the cDNA clones in Library A and 0.8% of Library B. Comparison of the deduced amino acid sequence of clone FA0035 to the sequences in the NRDB as described in Example 4 revealed no significant homology to any known protein sequences, and it is therefore categorized as an unknown open reading frame (ORF). The name "Daria" was arbitrarily assigned to this clone.

Clone FA0759, containing plasmid pFA0759, encoded a polypeptide of 187 amino acids with 72% amino acid sequence identity to a putative subunit of the vacuolar associated protein from *Neurospora crassa* (Trembl accession number P87252). This gene product did not appear to be a secreted protein as no signal peptide was detected using Signal-P software. Clone FA0759 was represented by approximately 2.0% of the cDNA clones in Library A and 1.5% of Library B.

Example 10: Cloning and nucleotide sequence analysis of genomic DNA segments

encoding unknown genes "Daria" and the putative vacuolar associated protein

Fusarium venenatum genomic DNA segments encoding the unknown secreted protein "Daria" and the putative vacuolar associated protein were isolated by screening the λ ZipLox library described in Examples 6 and 7. Radiolabeled cDNA inserts from plasmids pFA0035 and pFA0759 were used as probes to screen the library. Plaques which hybridized strongly to either probe using the same conditions in Example 7 were purified twice on *E. coli* Y1090ZL cells, and the individual clones were subsequently excised from the λ ZipLox vector as pZL1-derivatives (D'Alessio *et al.*, 1992, *supra*).

DNA sequence analysis revealed that one of these clones, containing a plasmid designated as pLC03, comprised the entire "Daria" coding region as well as 0.9 kb of 5'-flanking and 0.9 kb of 3'-flanking DNA encompassing the promoter and terminator regions, respectively. The nucleotide sequence (SEQ ID NO. 2) and deduced amino acid sequence (SEQ ID NO. 5) are shown in Figure 2. The coding region was punctuated by a single 55 bp intron.

Similarly, a genomic DNA clone was isolated through screening of the λ ZipLox library with a radiolabeled probe derived from the cDNA insert of pFA0579. The genomic clone, designated as pQUINN, encoded the entire vacuolar associated protein subunit plus 3.0 kb of 5'-flanking and 0.3 kb of 3'-flanking DNA comprising the promoter and terminator regions, respectively. The nucleotide sequence (SEQ ID NO. 3) and deduced amino acid sequence (SEQ ID NO. 6) are shown in Figure 3. Nucleotide sequence comparisons between the genomic and cDNA clones revealed the presence of a 594 bp intron in the 5'-untranslated region of the putative vacuolar associated protein subunit. In addition, the coding region contained a 77 bp intron.

Example 11: Construction of pDM181

Plasmid pDM181 was constructed using the technique of splice overlap extension to fuse the 1.2 kb *Fusarium oxysporum* trypsin promoter to the 1.1 kb *Fusarium oxysporum* trypsin terminator. A polylinker containing *Swa*I, *Kpn*I and *Pac*I restriction sites was inserted between the promoter and terminator as part of the overlapping PCR strategy. At the 5' end of the promoter a *Xho*I site was added and the native *Eco*RI site was preserved. At the 3' end of the terminator *Eco*RI, *Hind*III and *Nsi*I sites were incorporated by the PCR reaction.

A PCR fragment containing -1208 to -1 of the *Fusarium oxysporum* trypsin promoter plus a 25 base pair polylinker was generated from plasmid pJRoy20 (Royer *et al.*, 1995, *Biotechnology* 13: 1479-1483) using the following primers:

Primer 1 (sense): 5'-GAGCTCGAGGAATTCTTACAAACCTTCAAC-3' (SEQ ID NO.

5 7)

XhoI *EcoRI*

Primer 2 (antisense):

5'-TTAATTAAGGTACCTGAATTAAATGGTGAAGAGATAGATATCCAAG-3'

(SEQ ID NO. 8)

10 *PacI* *KpnI* *SwaI*

The 100 µl PCR reaction contained 10 ng of pJRoy20, 50 pmol of each primer, 1X *Pwo* buffer (Boehringer Mannheim, Indianapolis, IN), 200 µM each of dATP, dCTP, dGTP, and dTTP, and 5 units of *Pwo* DNA polymerase (Boehringer Mannheim, Indianapolis, IN). PCR conditions used were 95°C for 3 minutes followed by 25 cycles at 95°C for 30 seconds, 50°C for 1 minute, and 72°C for 1 minute. The final extension cycle was at 72°C for 5 minutes.

Using the same PCR conditions, a second PCR fragment containing base pairs -5 to -1 of the *Fusarium oxysporum* trypsin promoter, a 25 base pair polylinker, and 1060 base pairs of the 3' untranslated region of the *Fusarium oxysporum* trypsin gene (terminator region) was generated from plasmid pJRoy20 using the following primers:

20 Primer 3 (sense):

5'-TCACCATTAAATTCAGGTACCTTAATTAATTCCTTGTTGGAAGCGTCGA-3' (SEQ ID NO. 9)

SwaI *KpnI* *PacI*

25 Primer 4 (antisense):

5'-TGGTATGCATAAGCTTGAATTCAGGTAAACAAGATATAATTT-3' (SEQ ID NO. 10)

NsiI *HindIII* *EcoRI*

30 The final 2.3 kb overlapping PCR fragment which contained -1208 to -1 of the *Fusarium oxysporum* trypsin promoter, the 25 base pair polylinker and 1060 base pairs of the *Fusarium oxysporum* trypsin terminator was obtained using 0.2 µl of the first PCR (promoter) reaction and 3 µl of the second (terminator) reaction as templates and primers

1 and 4. The PCR conditions used were 95°C for 3 minutes followed by 30 cycles at 95°C for 30 seconds, 62°C for 1 minute, and 72°C for 3 minutes. The final extension cycle was at 72°C for 5 minutes. *Pwo* DNA polymerase was also used for this reaction.

The resulting 2.3 kb fragment containing the trypsin promoter, the polylinker, and the trypsin terminator was digested with *EcoRI* and ligated into the *EcoRI* digested vector pMT1612 containing the *bar* gene (WO 97/26330) to create pDM181 (Figure 4).

Example 12: Construction of plasmid pSheB1

The *Fusarium venenatum* expression vector pSheB1 (Figure 5) was generated by modification of pDM181. The modifications included (a) removal of two *NcoI* sites within the pDM181 sequence, and (b) restoration of the natural translation start of the *Fusarium oxysporum* trypsin promoter (reconstruction of an *NcoI* site at the ATG start codon).

Removal of two *NcoI* sites within the pDM181 sequence was accomplished using the QuikChange™ site-directed mutagenesis kit (Stratagene Cloning Systems, La Jolla, CA) according to the manufacturer's instruction with the following pairs of mutagenesis primers:

5'-dCAGTGAATTGGCCTCGATGGCCGCGGCCGCGAATT-3' plus (SEQ ID NO. 11)
5'-dAATTCGCGGCCGCGGCCATCGAGGCCAATTCAGT-3' (SEQ ID NO. 12)
20 5'-dCACGAAGGAAAGACGATGGCTTTCACGGTGTCTG-3' plus (SEQ ID NO. 13)
5'-dCAGACACCGTGAAAGCCATCGTCTTTCCTTCGTG-3' (SEQ ID NO. 14)

Restoration of the natural translation start of the *Fusarium oxysporum* trypsin promoter was also accomplished using the Stratagene QuikChange™ site directed mutagenesis kit in conjunction with the following pair of mutagenesis primers:

25 5'-dCTATCTCTTCACCATGGTACCTTAATTAAATACCTTGTTGGAAGCG-3' plus
(SEQ ID NO. 15)
5'-dCGCTTCCAACAAGGTATTTAATTAAAGGTACCATGGTGAAGAGATAG-3'
(SEQ ID NO. 16)

All site-directed changes were confirmed by DNA sequence analysis of the appropriate vector regions.

Example 13: Construction of pDM194 and pDM218

The 7.8 kb plasmid pDM194 (7.8 kb) used to obtain expression of *Thermomyces lanuginosus* (formerly designated *Humicola lanuginosa*) lipase in *Fusarium venenatum* has the following gene elements:

5 A 1.2 kb DNA segment containing the *Fusarium oxysporum* trypsin gene promoter (Royer *et al.*, 1995, *supra*).

A 0.9 kb DNA fragment containing the *Thermomyces lanuginosus* lipase cDNA (EP 305 216).

A 1.1 kb DNA segment containing the *Fusarium oxysporum* trypsin gene terminator (Royer *et al.*, 1995, *supra*).

10 A 4.7 kb fragment of DNA from pMT1612 (WO 98/11203) containing the 2.8 kb *E. coli* vector pUC19 and a 1.8 kb fragment comprising the *Aspergillus nidulans amdS* gene promoter (Hynes *et al.*, 1988, *Mol. Cell. Biol.* 8: 2589-2596), *Streptomyces hygroscopicus* phosphinothricin acetyltransferase (*bar*) gene (Thompson *et al.*, 1987, *EMBO Journal* 6: 2519-2514), and *Aspergillus niger* AMG terminator.

15 The *SwaI*/*PacI* lipase fragment was generated by PCR. Plasmid pMHan37 which contains the cDNA of the *Thermomyces lanuginosus* lipase gene (EP 305 216) was used as the template. PCR primers 5 and 6 shown below were used to introduce a *SwaI* site at the 5' end and a *PacI* site at the 3' end of the lipase coding region.

Primer 5 (sense):

20 5'-ATTTAAATGATGAGGAGCTCCCTTGTGCTG-3' (SEQ ID NO. 17)

SwaI

Primer 6 (anti-sense):

5'-TTAATTAACTAGAGTCGACCCAGCCGCGC-3' (SEQ ID NO. 18)

PacI

25 The 100 µl PCR reaction contained 10 ng of pMHan37, 50 pmol of each primer, 1X PCR buffer (Perkin-Elmer Corp., Branchburg, NJ), 250 µM each of dATP, dCTP, dGTP, and dTTP, and 5 units of *Taq* DNA polymerase (Perkin-Elmer Corp., Branchburg, NJ). The PCR conditions used were one cycle at 95°C for five minutes followed by 30 cycles at 95°C for 1 minute, 55°C for one minute, and 72°C for two minutes. The 0.9 kb
30 PCR product was subcloned into pCRII of the TA-Cloning Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Plasmid DNA was isolated using a Qiagen Maxiprep Kit (Qiagen, Santa Clarita, CA), digested with *SwaI* and *PacI*, and

electrophoresed on a 1% agarose gel for one hour at 100 volts. The 0.9 kb fragment was excised, purified using a SpinBind Kit (FMC, Rockland, ME), and cloned into pBANe6 (WO 98/11203) to produce pBANe8.

pBANe8 was digested with *SwaI* and *PacI* and the 0.9 kb lipase fragment was ligated to *SwaI/PacI* digested pDM181 yielding lipase expression plasmid pDM194 (Figure 6).

pDM218 was constructed from pJRoy35 (Figure 7). *NotI* and *PmeI* restriction sites were introduced at the 5' end of the *Fusarium oxysporum* trypsin promoter by PCR.

A 362 bp amplicon containing the 5' end of the promoter was produced using pDM194 as a template with the following primers:

multi1: 5'-ATAAGAATGCGGCCGCTAGTTTAAACTTACAAACCTTCAACAGTG-3'

(SEQ ID NO. 19)

multi 2: 5'-TAGCATCTATCTCCGTCTT-3' (SEQ ID NO. 20)

The 100 µl PCR reaction contained 150 ng of 3 kb *EcoRI* fragment, 50 pmol of each primer, 1X *Pwo* buffer, 200 µM each of dATP, dCTP, dGTP, and dTTP, and 5 units of *Pwo* DNA polymerase. The PCR conditions used were one cycle at 95°C for 3 minutes, 30 cycles at 95°C for 1 minute, 50°C for 1 minute, and 72°C for 1.5 minutes; followed by a 5 minute extension at 72°C. The amplicon was subcloned into vector pCR-Blunt (Invitrogen, Carlsbad, CA). A 0.25 kb *NotI/BcuI* fragment was electrophoresed on a 1% agarose gel for one hour at 100 volts, excised, and purified using a QIAquick Gel Extraction Kit (Qiagen, Santa Clarita, CA).

HpaI, *SnaBI*, and *PpuMI* sites were introduced at the 3' end of the *Fusarium oxysporum* trypsin terminator by PCR. A 714 bp amplicon containing the 3' end of the trypsin terminator was produced using the 3 kb *EcoRI* fragment as template with the following primers:

multi3: 5'-GTGTGCAGTGACCCAGAAT-3' (SEQ ID NO. 21)

multi4: 5'-GATTGGGTCCCTACGTAGTTAACACTATAGGCCATCGTTTAC-3' (SEQ ID NO. 22)

The 100 µl PCR reaction contained 50 pmol of each primer, 150 ng of the 3 kb *EcoRI* fragment, 1X *Pwo* buffer, 200 µM each of dATP, dCTP, dGTP, and dTTP, and 5 units of *Pwo* DNA polymerase. The PCR conditions used were identical to those listed

above. The amplicon was subcloned into vector pCR-Blunt. A 0.62 kb *NheI/PpuMI* fragment was isolated as described above.

A 2.3 kb *BcuI/NheI* fragment containing the 3' end of the *Fusarium oxysporum* trypsin promoter, the *Humicola lanuginosa* lipase gene (Geneseq nucleotide accession number N91076), and the 5' end of the *Fusarium oxysporum* trypsin terminator was isolated from pDM194.

The 0.25 kb *NotI/BcuI* fragment, 2.3 kb *BcuI/NheI* fragment, and 0.62 kb *NheI/PpuMI* fragments were cloned together into pDM194 partially digested with *NotI* and completely digested with *PpuMI* to create pDM218 (Figure 8).

10

Example 14: Construction of plasmid pMWR60

The plasmid pMWR60 was derived from the expression vector pEJG25A. pEJG25A was constructed by insertion of a phytase coding sequence from *Peniophora lycii* (WO 98/28408) into pDM181 (Example 11) as follows:

15 First, two synthetic oligonucleotide primers shown below were designed to amplify the *Peniophora lyci* phytase coding sequence from plasmid pA1phy2 (WO 98/28408) as template by PCR.

Forward primer: 5'-ATTTAAATATGGTTTCTTCGGCATTCGC-3' (SEQ ID NO. 23)

20 Reverse primer: 5'-TTAATTAAC**TATTCCGACGGAACAAAGC**-3' (SEQ ID NO. 24)

(Bold letters represent coding sequence).

Each 100 µl *Pwo* polymerase reaction contained 50 pmol of each primer, 1 ng of template DNA, 2 µl of 10 mM dNTPs, 1X *Pwo* polymerase buffer, and 2.5 units of *Pwo* polymerase. The reactions were incubated in a Perkin Elmer Model 9600 Thermal
25 Cycler programmed as follows: One cycle at 94°C for 2 minutes, 55°C for 30 seconds, and 72°C for 1 minute; 9 cycles at 94°C for 15 seconds, 55°C for 30 seconds, and 72°C for 1 minute; 15 cycles at 94°C for 15 seconds, 55°C for 30 seconds, and 72°C for 1 minute, with an extension of 20 seconds per cycle; a final cycle at 94°C for 15 seconds,
30 55°C for 30 seconds, and 72°C for 7 minutes; and a soak cycle at 4°C. The reaction product was electrophoresed on a 1% agarose gel for one hour at 100 volts. The 1.3 kb band was excised and purified using Qiaex II. The purified PCR product was

subsequently cloned into the plasmid pCR2.1 (Invitrogen, Carlsbad, CA) and used to transform *E. coli* TOP10 cells (Invitrogen, Carlsbad, CA). Plasmid DNA was isolated from several of the transformant colonies and analyzed by DNA sequencing to ensure that no mutations were introduced during the PCR. Subsequently one phytase clone was digested with restriction endonucleases *Swa*I and *Pac*I. The fragments were electrophoresed on a 1% agarose gel for one hour at 100 volts, excised, and purified using Qiaex II. The 1.3 kb phytase gene fragment was ligated with pDM181 (Example 11) that had been previously cut with *Swa*I and *Pac*I, resulting in the expression plasmid pEJG25A (Figure 9).

In order to remove extraneous linker sequences in the 5'-flanking DNA, pEJG25A was mutagenized using the Quick-Change™ site-directed mutagenesis kit in combination with the following oligonucleotide primers to obtain the vector pMWR60-Int2:

primer A: 5'-CTCTTGGATATCTATCTCTTCACCATGGTTTCTTCGGCATTCGC-3' (SEQ ID NO. 25)

primer B: 5'-GCGAATGCCGAAGAAACCATGGTGAAGAGTAGATATCCAAGAG-3' (SEQ ID NO. 26)

The designed nucleotide changes were verified by DNA sequence analysis.

pMWR60-Int2 was then digested with *Sfu*I plus *Nhe*I, and the 1.8 kb fragment was electrophoresed on a 1% agarose gel for one hour at 100 volts, excised, and purified using Qiaex II. The isolated fragment was ligated with the *Sfu*I-*Nhe*I vector fragment of pDM218 to generate a new intermediate called pMWR60-Int3. This intermediate was cleaved with *Not*I, and a 5.35 kb fragment was purified as above. The purified fragment was ligated with pSheB1 (described in Example 12) which had been previously digested with *Not*I. The resulting intermediate was designated as pMWR60-Int4a. pMWR60-Int4a was then cut with *Bsp*LU11I plus *Nhe*I, and a 5.25 kb segment was purified as above. This isolated segment was ligated with pSheB1, which had also been digested with *Bsp*LU11I plus *Nhe*I, and purified as above. The resulting vector product was named pMWR60 (Figure 10).

Example 15: Generation of a lipase reporter gene

For the construction of variants of a *Humicola lanuginosa* lipase known as

LIPOLASE™ (Novo Nordisk A/S, Bagsværd, Denmark), the Chameleon double-stranded, site-directed mutagenesis kit was used according to the manufacturer's instructions.

5 The gene encoding the LIPOLASE™ enzyme was obtained from pAHL (WO 92/05249). In accordance with the manufacturer's instructions, the *ScaI* site of the ampicillin gene of pAHL was changed to a *MluI* site by use of the primer 7258, thus changing the *ScaI* site found in the ampicillin resistance gene and used for cutting to a *MluI* site.

Primer 7258: 5'-GAATGACTTGGTTGACGCGTCACCAGTCAC-3' (SEQ ID NO. 27)

10 The pAHL vector comprising the LIPOLASE™ gene was then used as a template for DNA polymerase with oligos 7258 and 7770, thus changing the *ScaI* site found in the LIPOLASE™ gene and without changing the amino acid sequence site.

Primer 7770: 5'-TCTAGCCCAGAATACTGGATCAAATC-3' (SEQ ID NO. 28)

15 The desired mutation (*e.g.*, the introduction of a cysteine residue) was introduced into the LIPOLASE™ gene by addition of an appropriate oligos comprising the desired mutation.

Site directed mutagenesis as described above was used to construct a plasmid harboring a gene encoding the LIPOLASE™ variant 1S, E239C, Q249R using the following primers:

20 Primer 106659 shown below was used to introduce E99N,N101S.

Primer 107581:

5'-CTTAACTTTGACTTGAAAAACATATCTGACATTTGCTCC-3' (SEQ ID NO. 29)

Primer 101782 shown below was used to introduce SPPCGRRP (-E).

Primer 101782:

25 5'-GGACGGCCTTGGCTAGCCCTCCGTGCGGCCGCCGGCCGGTCTCGCAGGATC
TGTTTAAC-3' (SEQ ID NO. 30)

Primer 9639 shown below was used to introduce E239C.

Primer 9639: 5'-ATATCGTGAAGATATGCGGCATTGATGCCACC-3' (SEQ ID NO.
31)

30 Primer 8829 shown below was used to introduce Q249R.

Primer 8829: 5'-GGCGGCAATAACCGGCCGAACATTCCGGATATCCC-3' (SEQ ID
NO. 32)

The mutations were verified by sequencing the entire gene. The resulting plasmid was designated pEV1163.

Example 16: Construction of pRaMB60

- 5 Plasmid pRaMB60 was constructed by ligating the 6.5 kb *SfuI-NheI* vector fragment from pMWR60 with a 0.5 kb *SfuI-NheI* fragment from pSheB1. All fragments were isolated by agarose gel electrophoresis and purified from gel slices using BioRad Prep-a-Gene reagents (BioRad Laboratories, Hercules, CA).

10 **Example 17: Construction of plasmid pRaMB62, an expression vector containing the glucoamylase promoter**

A unique *BspLU11I* site was generated by site-directed mutagenesis of plasmid pFAMG using the following primers in combination with the Quick-Change™ mutagenesis kit :

- 15 primer 1: 5'-dCACTGCTATCACCAACATGTTTACTCAAGTCC-3' (SEQ ID NO. 33)
primer 2: 5'-dGGACTTGAGTAAACATGTTGGTGATAGCAGTG-3' (SEQ ID NO. 34)

The site-directed change was verified by DNA sequencing, and the resulting plasmid derivative was designated pMWR62-Int1.

- 20 Next, the lipase reporter gene described in Example 15 was amplified by PCR using plasmid pEV1163 as template with the following primers which introduced a *BspHI* site near the start codon and a *PacI* site following the stop codon of the lipase coding region:

- forward primer: 5'-GACTCATGAGGAGCTCCCTTGTGCTGTTC-3' (SEQ ID NO. 35)
25 reverse primer: 5'-TGATTAATTAACCTAAAGACATGTCCCAATTAAC-3' (SEQ ID NO. 36)

The PCR reaction was composed of 1 µl of template DNA (10 ng), 1 µl of forward primer (77 pmol), 1 µl of reverse primer (81 pmol), 10 µl of 10X *Pwo* polymerase buffer, 16 µl of 1.25 mM dNTP mix, and 1 µl (2.5 units) of *Pwo* polymerase.

- 30 The reaction was incubated in a Perkin-Elmer Model 480 thermocycler using the following temperature settings: One cycle at 95°C for 5 minutes; 30 cycles at 95°C for 1 minute, 47°C for 1 minute, and 68°C for 2 minutes; and a 4°C soak cycle.

The amplified product was then digested with *Bsp*HI plus *Pac*I, purified by agarose gel electrophoresis (Example 16), and used in a three-part ligation with the 5.8 kb *Pme*I-*Nco*I fragment of pRaMB60 and the 2.1 kb *Stu*I-*Bsp*LU11I fragment from pMWR62-int1. The resulting vector, designated pRaMB62 (Figure 11), contained the
5 lipase reporter gene under the transcriptional control of the *Fusarium venenatum* glucoamylase promoter.

Example 18: Construction of plasmid pRaMB64, an expression vector containing the "Daria" promoter

10 The promoter region from pECO3 (Example 10), termed the "Daria" promoter, was amplified using PCR in combination with the following primer pair that were designed to introduce *Swa*I and *Bsp*LU11I sites at the 5' and 3' ends of the promoter segment, respectively:

primer 1: 5'-GCATTAAATTACTACTGTGATGTG-3' (SEQ ID NO. 37)

15 primer 2: 5'-GATTGATGTGAAACACATGTTGATG-3' (SEQ ID NO. 38)

The PCR reaction was composed of 1 µl of pECO3 (10 ng), 1 µl of forward primer (50 pmol), 1 µl of reverse primer (50 pmol), 10 µl of 10X *Pwo* polymerase buffer, 16 µl of 1.25 mM dNTP mix, and 1 µl (2.5 units) of *Pwo* polymerase. The reaction was incubated in a Perkin-Elmer Model 480 thermocycler using the following temperature
20 settings: One cycle at 95°C for 5 minutes; 30 cycles at 95°C for 1 minute, 47°C for 1 minute, and 68°C for 2 minutes; and a 4°C soak cycle.

The 0.9 kb PCR product was electrophoresed on a 1% agarose gel for one hour at 100 volts, excised, and purified using Qiaex II.

The amplified DNA segment was subcloned into pCR2.1 (Invitrogen, Carlsbad, CA) and analyzed by restriction enzyme cleavage with *Swa*I, *Bsp*LU11I, *Eco*RI, and *Xho*I to verify that it was correct. The plasmid generated in this manner, termed pECO4, was digested with *Swa*I plus *Bsp*LU11I, and the 0.9 kb promoter fragment was purified by gel electrophoresis as described in Example 16. The purified fragment was mixed in a three-part ligation with the 5.8 kb *Pme*I-*Nco*I fragment of pRaMB60 and the 0.9 kb
30 *Bsp*HI-*Pac*I segment encoding the lipase reporter gene. The product of this ligation, pRaMB64 (Figure 12), contained the "Daria" promoter directing expression of the lipase reporter gene.

Example 19: Construction of plasmid pRaMB66, an expression vector containing the promoter derived from the vacuolar associated protein gene

The promoter segment from pQUINN (Example 10), encoding a putative
5 vacuolar associated protein, was amplified by PCR with the following primers which introduced a *SmaI* site and an *NcoI* site at the 5' and 3' ends of the promoter, respectively:
primer 1: 5'-dCGACCCGGGAATTAGAGAGGTTAGG-3' (SEQ ID NO. 39)
primer 2: 5'-dCGTATAACCCATGGTGGACTTGTCGGAC-3' (SEQ ID NO. 40)

The PCR reaction was composed of 1 µl of pQUINN (10 ng), 1 µl of forward
10 primer (50 pmol), 1 µl of reverse primer (50 pmol), 10 µl of 10X *Pwo* polymerase buffer, 16 µl of 1.25 mM dNTP mix, and 1 µl (2.5 units) of *Pwo* polymerase. The reaction was incubated in a Perkin-Elmer Model 480 thermocycler using the following temperature settings: One cycle at 95°C for 5 minutes; 30 cycles at 95°C for 1 minute, 47°C for 1 minute, and 68°C for 2 minutes; and a 4°C soak cycle.

15 The 3.1 kb amplified DNA fragment was electrophoresed on a 1% agarose gel for one hour at 100 volts, excised, and purified using Qiaex II.

The 3.1 kb amplified DNA fragment was subcloned into pCR-Script (Stratagene, La Jolla, CA) to generate the intermediate plasmid pQUINN-promoterA. Two restriction fragments were isolated from this plasmid; a 2.4 kb *SmaI-NdeI* fragment, and a 0.7 kb
20 *NdeI-NcoI* fragment (together these segments span the entire promoter region). The isolated fragments were combined in a four-part ligation with the 8 kb *PmeI-NcoI* fragment of pRaMB60 and the 0.9 kb *BspHI-PacI* segment encoding the lipase reporter gene described in the previous examples. The product of this ligation, pRaMB66 (Figure 13), contained the lipase reporter gene under the transcriptional control of the putative
25 vacuolar associated protein gene promoter.

Example 20: Expression of the lipase reporter gene in *Fusarium venenatum* under control of the AMG, "Daria" and vacuolar associated protein promoters

Spores of *Fusarium venenatum* CC1-3 (MLY-3) were generated by inoculating a
30 flask containing 500 ml of RA sporulation medium with 10 plugs from a 1X Vogels medium plate (2.5% Noble agar) supplemented with 2.5% glucose and 2.5 mM sodium nitrate and incubating at 28°C, 150 rpm for 2 to 3 days. Spores were harvested through

Miracloth (Calbiochem, San Diego, CA) and centrifuged 20 minutes at 7000 rpm in a Sorvall RC-5B centrifuge (E. I. DuPont De Nemours and Co., Wilmington, DE). Pelleted spores were washed twice with sterile distilled water, resuspended in a small volume of water, and then counted using a hemocytometer.

5 Protoplasts were prepared by inoculating 100 ml of YEPG medium with 4×10^7 spores of *Fusarium venenatum* CC1-3 and incubating for 16 hours at 24°C and 150 rpm. The culture was centrifuged for 7 minutes at 3500 rpm in a Sorvall RT 6000D (E. I. DuPont De Nemours and Co., Wilmington, DE). Pellets were washed twice with 30 ml of 1 M MgSO_4 and resuspended in 15 ml of 5 mg/ml of NOVOZYME 234™ (batch PPM 10 4356, Novo Nordisk A/S, Bagsværd, Denmark) in 1 M MgSO_4 . Cultures were incubated at 24°C and 150 rpm until protoplasts formed. A volume of 35 ml of 2 M sorbitol was added to the protoplast digest and the mixture was centrifuged at 2500 rpm for 10 minutes. The pellet was resuspended, washed twice with STC, and centrifuged at 2000 rpm for 10 minutes to pellet the protoplasts. Protoplasts were counted with a 15 hemocytometer and resuspended in an 8:2:0.1 solution of STC:SPTC:DMSO to a final concentration of 1.25×10^7 protoplasts/ml. The protoplasts were stored at -80°C, after controlled-rate freezing in a Nalgene Cryo 1°C Freezing Container (VWR Scientific, Inc., San Francisco, CA).

20 Frozen protoplasts of *Fusarium venenatum* CC1-3 were thawed on ice. Five to ten µg of pRaMB62, pRaMB64, and pRaMB66 (described in Examples 17-19) and 5 µl of heparin (5 mg per ml of STC) were added to separate 50 ml sterile polypropylene tubes. One hundred µl of protoplasts was added to each tube, mixed gently, and incubated on ice for 30 minutes. One ml of SPTC was added and incubated 20 minutes at room temperature. After the addition of 25 ml of 40°C COVE top agarose, the mixture 25 in each tube was poured onto an empty 150 mm diameter plate and incubated overnight at room temperature. Approximately 24 hours later, an additional 25 ml of 40°C COVE top agarose containing 10 mg of BASTA™ per ml was poured on top of the plate and incubated at room temperature for up to 14 days. The active ingredient in the herbicide BASTA™ is phosphinothricin. BASTA™ was obtained from AgrEvo (Hoechst 30 Schering, Rodovre, Denmark) and was extracted twice with phenol:chloroform:isoamyl alcohol (25:24:1), and once with chloroform:isoamyl alcohol (24:1) before use.

The transformants were picked directly from the selection plates (COVE underlay

with COVE-BASTA™ overlay) into 125 ml shake flasks containing 25 ml of M400Da medium supplemented with 1 mM CaCl₂ and 100 µg/ml ampicillin (to prevent bacterial contamination) and incubated at 28°C, 200 rpm on a platform shaker for 7 days. The untransformed-recipient strain was also included as a negative control.

- 5 Flasks were sampled at 7 days. Cells were removed by centrifugation, and 10 µl of each supernatant sample was heated to 95°C for 5 minutes with an equal volume of Tris-glycine sample buffer (Novex Experimental Technology, San Diego, CA). The denatured supernatant proteins were separated on a 10-20% Tris-glycine gradient gel (Novex Experimental Technology, San Diego, CA) and stained with Coomassie blue.
- 10 SDS-PAGE analysis showed that the lipase-producing transformants secrete a prominent polypeptide with an apparent molecular weight of approximately 43 kDa.

Similarly, cell-free culture broths from each transformant were assayed for lipase activity using *p*-nitrophenylbutyrate as the substrate (Royer *et al.*, 1995, *supra*).

- The results shown in Table 1 demonstrated that active lipase was expressed and
- 15 secreted using the *Fusarium venenatum* promoter elements present in pRaMB62, pRaMB64, and pRaMB66.

Table 1

Vector used	Promoter	Transformant	Lipase yield (LU/ml)
None	--	negative control	< 1.0
pRaMB62	glucoamylase	RaMB62.1	1158
"	"	RaMB62.2	500
"	"	RaMB62.3	1379
"	"	RaMB62.4	1678
"	"	RaMB62.5	702
"	"	RaMB62.6	616
"	"	RaMB62.7	473
"	"	RaMB62.8	894
"	"	RaMB62.9	564
"	"	RaMB62.10	1036
"	"	RaMB62.11	2731
"	"	RaMB62.12	1960

"	"	RaMB62.13	1682
"	"	RaMB62.14	572
"	"	RaMB62.15	1421
pRaMB64	"Daria"	RaMB64.1	1217
"	"	RaMB64.2	561
"	"	RaMB64.3	875
"	"	RaMB64.4	839
"	"	RaMB64.5	1449
"	"	RaMB64.6	354
"	"	RaMB64.7	377
"	"	RaMB64.8	184
"	"	RaMB64.9	1967
"	"	RaMB64.10	657
"	"	RaMB64.11	883
"	"	RaMB64.12	184
"	"	RaMB64.13	1935
"	"	RaMB64.14	1049
"	"	RaMB64.15	875
pRaMB66	Vacuolar associated protein	RaMB66.1	1990
"	"	RaMB66.2	165
"	"	RaMB66.3	380
"	"	RaMB66.4	155
"	"	RaMB66.5	170
"	"	RaMB66.6	145
"	"	RaMB66.7	180
"	"	RaMB66.8	420
"	"	RaMB66.9	200
"	"	RaMB66.10	195
"	"	RaMB66.11	190
"	"	RaMB66.12	165

"	"	RaMB66.13	140
"	"	RaMB66.14	435
"	"	RaMB66.15	125

Example 21: Comparative expression of the *Humicola lanuginosa* lipase reporter gene under control of *Fusarium venenatum* amyloglucosidase and *Fusarium oxysporum* trypsin promoters

5 *Fusarium venenatum* CC1-3 transformants containing either pRamB64 (Example 17) or pDM218 (Example 13), prepared as described in Example 20, were cultivated for 180 hours at 29°C, 1200 rpm, pH 6.25 in 2 liter fermentors containing suitable carbon, nitrogen, and trace metals sources and supplemented with either urea or ammonium phosphate as the feed. Cell-free culture broths from each fermentation were assayed at
10 18 to 24 hour intervals for lipase activity using *p*-nitrophenylbutyrate as the substrate (Royer *et al.*, 1995, *supra*) for 180 hours.

Figure 14 shows comparative expression of the *Humicola lanuginosa* lipase reporter gene in *Fusarium venenatum* under control of either the *Fusarium venenatum* amyloglucosidase (pAMG) promoter or *Fusarium oxysporum* trypsin (pSP387) promoter.

15 The results demonstrated higher levels of lipase activity with the *Fusarium venenatum* amyloglucosidase promoter than the *Fusarium oxysporum* trypsin promoter whether urea or ammonium phosphate was used as the source of nitrogen in the feed. Moreover, higher levels of lipase activity were observed using ammonium phosphate in the feed

20

Deposit of Biological Materials

The following biological materials have been deposited under the terms of the Budapest Treaty with the Agricultural Research Service Patent Culture Collection, Northern Regional Research Center, 1815 University Street, Peoria, Illinois, 61604, and
25 given the following accession numbers:

Deposit	Accession Number	Date of Deposit
<i>E. coli</i> TOP10 (pECO3)	NRRL B-30067	October 27, 1998
<i>E. coli</i> TOP10 (pFAMG)	NRRL B-30071	October 27, 1998
<i>E. coli</i> DH10B (pQUINN)	NRRL B-30076	October 27, 1998

The strains have been deposited under conditions that assure that access to the culture will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122. The deposits represent substantially pure cultures of the deposited strains. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. In the case of conflict, the present disclosure including definitions will control.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>53</u> , line <u>27</u> .	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL)	
Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit October 27, 1998	Accession Number NRRL B-30067
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No. 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

This sheet was received with the international application
Authorized officer For Meadows Operations - IAPD Team 1 (703) 305-3745 (703) 305-2230 (FAX)

For International Bureau use only

This sheet was received with the International Bureau on:
Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>53</u> , line <u>28</u> .	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL)	
Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit October 27, 1998	Accession Number NRRL B-30071
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No. 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

This sheet was received with the international application
Authorized officer 8 703) 305-3745 (T), 305-3230 (FAX)

For International Bureau use only

This sheet was received with the International Bureau on:
Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>53</u> , line <u>29</u> .	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL)	
Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit October 27, 1998	Accession Number NRRL B-30076
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No. 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

This sheet was received with the international application
Authorized officer: <u>Sh. Meadows</u> PCT Section - App Team 1 <u>Sh</u> 1000-1000-1000 1000 (EPC)

For International Bureau use only

This sheet was received with the International Bureau on:
Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>54</u> , line <u>1</u> .	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL)	
Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit October 27, 1998	Accession Number NRRL B-30073
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No. 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

This sheet was received with the international application
Authorized officer Shel Meadows PCT Operations - IAPD Team 1 (703) 305-3745 (703) 305-3230 (FAX)

For International Bureau use only

This sheet was received with the International Bureau on:
Authorized officer

Claims

What is claimed is:

- 5 1. A method for producing a polypeptide, comprising:
(a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first nucleic acid sequence encoding the polypeptide operably linked to a second nucleic acid sequence comprising a promoter foreign to the first nucleic acid sequence, wherein the promoter comprises a
10 sequence selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3, and subsequences thereof; and mutant, hybrid, and tandem promoters thereof; and
(b) isolating the polypeptide from the cultivation medium.
- 15 2. The method of claim 1, wherein the promoter comprises the nucleic acid sequence of nucleotides 1 to 3949 of SEQ ID NO. 1 or a mutant, hybrid, or tandem promoter thereof.
3. The method of claim 2, wherein the promoter comprises the nucleic acid
20 sequence of nucleotides 1 to 3949 of SEQ ID NO. 1.
4. The method of claim 3, wherein the promoter comprises the nucleic acid sequence contained in plasmid pECO3 which is contained in *E. coli* NRRL B-30067.
- 25 5. The method of claim 1, wherein the promoter comprises the nucleic acid sequence of nucleotides 1 to 938 of SEQ ID NO. 2 or a mutant, hybrid, or tandem promoter thereof.
6. The method of claim 5, wherein the promoter comprises the nucleic acid
30 sequence of nucleotides 1 to 938 of SEQ ID NO. 2.
7. The method of claim 6, wherein the promoter comprises the nucleic acid

sequence contained in plasmid pFAMG which is contained in *E. coli* NRRL B-30071.

8. The method of claim 1, wherein the promoter comprises the nucleic acid sequence of nucleotides 1 to 3060 of SEQ ID NO. 3, a subsequence thereof; or a mutant, hybrid, or tandem promoter thereof.

9. The method of claim 8, wherein the promoter comprises the nucleic acid sequence of nucleotides 1 to 3060 of SEQ ID NO. 3.

10. The method of claim 9, wherein the promoter comprises the nucleic acid sequence contained in plasmid pQUINN which is contained in *E. coli* NRRL B-30075.

11. The method of any of claims 1, 2, 5, and 8 wherein the mutant promoter is comprised of a substitution, deletion, and/or insertion of one or more nucleotides of a promoter selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3, wherein the mutant promoter has more or less promoter activity than the corresponding promoter.

12. The method of any of claims 1, 2, 5, and 8, wherein the hybrid promoter is comprised of portions of two or more promoters.

13. The method of claim 12, wherein the hybrid promoter comprises one or more portions selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3.

14. The method of claim 13, wherein the hybrid promoter further comprises a portion of another promoter.

15. The method of claim 1, wherein the tandem promoter is comprised of two or more promoters.

16. The method of claim 15, wherein the tandem promoter comprises two or more promoters selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3.
- 5 17. The method of claim 16, wherein the tandem promoter further comprises another promoter.
18. The method of claim 15, wherein the two or more promoters of the tandem promoter simultaneously promote the transcription of the nucleic acid sequence.
- 10 19. The method of claim 15, wherein one or more of the two or more promoters of the tandem promoter promote the transcription of the nucleic acid sequence at different stages of growth of the fungal host cell.
- 15 20. The method of any of claims 1-19, wherein the fungal host cell contains one or more copies of the nucleic acid sequence.
21. The method of any of claims 1-19, wherein the fungal host cell contains one copy of the nucleic acid sequence.
- 20 22. The method of any of claims 1-21, wherein the nucleic acid sequence encodes a polypeptide heterologous to the fungal host cell.
23. The method of any of claims 1-22, wherein the polypeptide is hormone or hormone variant, enzyme, receptor or portion thereof, antibody or portion thereof, or reporter.
- 25 24. The method of claim 23, wherein the enzyme is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase.
- 30 25. The method of claim 23, wherein the enzyme is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin

glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.

5

26. The method of any of claims 1-25, wherein the nucleic acid sequence is contained in the chromosome of the fungal host cell.

10

27. The method of any of claims 1-25, wherein the nucleic acid sequence is contained on an extrachromosomal element.

28. The method of any of claims 1-27, wherein the fungal host cell is a filamentous fungal or yeast cell.

15

29. The method of claim 28, wherein the filamentous fungal cell is an *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.

20

30. The method of claim 28, wherein the yeast cell is a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

31. The method of claim 28, wherein the filamentous fungal host cell is an *Aspergillus* cell.

25

32. The method of claim 28, wherein the filamentous fungal host cell is a *Fusarium* cell.

30

33. An isolated promoter sequence comprising a nucleic acid sequence selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3, and subsequences thereof; and mutant, hybrid, and tandem promoters thereof.

34. The promoter sequence of claim 33, comprising the nucleic acid sequence of nucleotides 1 to 3949 of SEQ ID NO. 1 or a subsequence thereof; or a mutant, hybrid, or tandem promoter thereof.

5 35. The isolated promoter sequence of claim 34, comprising the nucleic acid sequence of nucleotides 1 to 3949 of SEQ ID NO. 1.

36. The isolated promoter sequence of claim 35, comprising the nucleic acid sequence contained in plasmid pECO3 which is contained in *E. coli* NRRL B-30067.

10

37. The isolated promoter sequence of claim 33, comprising the nucleic acid sequence of nucleotides 1 to 938 of SEQ ID NO. 2 or a subsequence thereof; or a mutant, hybrid, or tandem promoter sequence thereof.

15 38. The isolated promoter sequence of claim 37, comprising the nucleic acid sequence of nucleotides 1 to 938 of SEQ ID NO. 2.

39. The isolated promoter sequence of claim 38, comprising the nucleic acid sequence contained in plasmid pFAMG which is contained in *E. coli* NRRL B-30071.

20

40. The isolated promoter sequence of claim 33, comprising the nucleic acid sequence of nucleotides 1 to 3060 of SEQ ID NO. 3 or a subsequence thereof; or a mutant, hybrid, or tandem promoter sequence thereof.

25 41. The isolated promoter sequence of claim 40, comprising the nucleic acid sequence of nucleotides 1 to 3060 of SEQ ID NO. 3.

42. The isolated promoter sequence of claim 41, comprising the nucleic acid sequence contained in plasmid pQUINN which is contained in *E. coli* NRRL B-30075.

30

43. The isolated promoter sequence of any of claims 33-42 which has at least 20% of the promoter activity of the sequence of nucleotides 1 to 3949 of SEQ ID NO. 1,

nucleotides 1 to 938 of SEQ ID NO. 2, or nucleotides 1 to 3060 of SEQ ID NO. 3.

44. An isolated promoter sequence having the same promoter activity as the promoter sequence of any of claims 33-43.

5

45. An isolated promoter sequence comprising a nucleic acid sequence having at least one mutation in the sequence of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, or nucleotides 1 to 3060 of SEQ ID NO. 3, or a subsequence thereof; in which the mutant promoter has the promoter activity.

10

46. A nucleic acid construct comprising a nucleic acid sequence encoding a polypeptide operably linked to the promoter of any of claims 33-45.

15

47. A recombinant expression vector comprising the nucleic acid construct of claim 46.

48. A recombinant host cell comprising the nucleic acid construct of claim 46.

49. A method for producing a polypeptide, comprising (a) cultivating a homologously recombinant cell, having incorporated therein a new transcription unit comprising a promoter of any of claims 33-45, an exon, and/or a splice donor site operably linked to a second exon of an endogenous nucleic acid sequence encoding the polypeptide, under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

25

50. A method for obtaining a mutant promoter, comprising:

30

(a) hybridizing a DNA under low stringency conditions with a nucleic acid sequence comprising (i) SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, (ii) the cDNA sequence contained in SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii); and

(b) isolating the mutant promoter from the DNA.

51. A method for obtaining a mutant promoter, comprising (a) introducing at least one mutation into the promoter of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, or nucleotides 1 to 3060 of SEQ ID NO. 3, wherein the mutant promoter has promoter activity; and (b) isolating the mutant promoter.

5

52. An isolated nucleic acid sequence, selected from the group consisting of:

(a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 65% identity with amino acids 22 to 581 of SEQ ID NO. 4, amino acids 19 to 200 of SEQ ID NO. 5, or amino acids 1 to 187 of SEQ ID NO. 6 ;

10 (b) a nucleic acid sequence having at least 65% homology with nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3;

(c) a nucleic acid sequence which hybridizes under very low, low, medium, medium-high, high, or very high stringency conditions with (i) nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3; (ii) the cDNA sequence contained in nucleotides 4013 to 5743 of SEQ ID NO. 1, nucleotides 993 to 1593 of SEQ ID NO. 2, or nucleotides 3061 to 3678 of SEQ ID NO. 3; (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii);

20 (d) a nucleic acid sequence encoding a variant of the polypeptide having an amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6 comprising a substitution, deletion, and/or insertion of one or more amino acids;

(e) an allelic variant of (a), (b), or (c); and

(f) a subsequence of (a), (b), (c), or (e).

25

53. A nucleic acid construct comprising the nucleic acid sequence of claim 52 operably linked to one or more control sequences which direct the production of the polypeptide in a suitable expression host.

30 54. A recombinant expression vector comprising the nucleic acid construct of claim 53, a promoter, and transcriptional and translational stop signals.

55. A recombinant host cell comprising the nucleic acid construct of claim 53.
56. A polypeptide encoded by the nucleic acid sequence of claim 52.

1/24

AATTTCGTCGATAGCGAGGACTCCTGGCCCTCGAATTAGTTAGCGTATCAGTGTAAG 60
TGCTGGGTTCTCCAGGCGTAAGTAAATTGAACCAGATGTTAGCTCCAGATTTCGCCCCG 120
AAGCCGGTTGGCAGACCAACGCGATAAGTTTATGGAAAGTTGGTTGGCGGATCAATGT 180
AAAGTTCCCTGCCATTGTCACGCAGATACTCGGCCCAAGACGCATCTTTGCCCTATCGCG 240
CAACTTTTGGGTCCCAGGATATCGGAAGAGCATTCCTAAGCCAGCATCTGGTGGGAG 300
ATCGTTCTTCTTATCTTCGGTCTTAAAGATGTTCAAGATAACTCAGCAGCAACTCG 360
ACGCAACTTGGCTACGTTGCCAACGCCCTGCTCTAAGACCCCTTTGAGGCCGTCACAGAA 420
ACGTTGCGAGGACTGTCTGGTTCCAGCGAGATGGATTGTTATGCGTTGTTCTCGGGGTC 480
TCTCTTGCTTTAGAGGTATCGGCAAGAGGCCATTCCACGTAGTCAGAGCGAGTGCGAA 540
CTATAACCGCAACGTCAGAAATTGTACCATGCAAGATTTTATACCACATACCTGGAA 600
GTTCTGGCTATTCAAGCGCTCTACCCCTTCGTTATAGCACATAAAGGAAATGTGAATCCATT 660
GCCACTGGGTCCCTCCGTGTCTGGCCGGTAAAGCGGTGAGGTGAAAGGCTAGC 720
AGATTGCACAAAGCTAGTGGGTGTTGTGAGAAAGCACATGTAAATGCTCTGACAGGTGTAG 780
CTTGCCAGCATAA TGCCATCCTCGATCGTGATCCTTATCACCGTGAGTAGCGTTGGAGGG 840
CGGGATAGTAAGCTCGGCGTTGATCTCGTAGAGGGCGCCTGAGAGGGCGGCAAGCGAAA 900
TTGGCTCTGAAATAGCGATGACTTTGAGGGATTCCGATCTGAACTGGATAGATTGAGCCC 960
CTGGGTAGGATCGATAAGCTGCTGGGCTTTTGAACGATGTTGGTGAAGTTCGAAAACAT 1020
GATTTCGGTCAGCGGCGCATGACGAGGGGGTTCCGGTCCAGGAGGGAGGTCCGGGCTGA 1080
GCTTGAAGGAGATGCAAGACACGAAGCGAAAGACACGAAGAGAGCGCAAGAGTCTGAGTA 1140
TGTGCAACCAGGCTCGAATAAGTGCAAGGCAGGACGAAAGTACGGAATAGACGATAGAATT 1200
GAGTATAGAAAGGCTGAATGGAAGATGGAGACGAGTTATAGGACGGTGGAGATAGAGTGG 1260
AGTTGAAGTTGAACGAAGCTGCGTCAGGTCCAGATACGGGAGACTGGCCATCAACTACTG 1320
GCCAGGTAGCCAGGGCGGATGGGCGGTTGGCAGGGTCCGGGGGGGACCTCAGGGGCAT 1380
TCCTTTCTCCAAGGGCGCTGGGGCTATGGACGGGCTGGCTGAACTCCAGCCGTCATGG 1440

Fig. 1A

2/24

GATAGCGGTGCAAGAGATCAGGTACTAAGTCTACCATGATAATTAGGGGCAGAGAAAA 1500
ATGATATATTGTTAGTAGTAAGCGGGTTTTTACAGTTGAGGAACCAACCTTCTTCATT 1560
TATTTATTCTTTCTCTGCAATTCAGTCCTTTTCTTAAATAGAAATATCTACCAATG 1620
GAACGGCTGGCTGAAGTGGCTGAAGAAATATAGCTCGAGCTGTCAAACCGCTCATCCTAC 1680
TACCCCTAGGTATAAAGCTGGGAACCTAAGACTCATTTCTATCCAACTCATCATATTGGGAG 1740
TTAGTGTAGACCTGTCGGCCTAGAGAAATATGTGTATCTGCATACTTTCAAATACCCCTACG 1800
TATACCCACTATGTTTAGCACAAATCATTTGACCTCTCAAGGCTCACCCATCTCAACACCT 1860
GTCGTGTGCTCACTTGACTACTTCTTTGAACCAAGCTCGCCATCGGACTAGTCGAACAAGC 1920
TTGTCGCCCCCATACAGATGAATGTATGTTTAAAGCTACATGATCAGCCTGAACCGAGCA 1980
TAACTCGAGTGCCGAGACTCCTCTGATGTATATCGAGATGAATGACAAACCTACGGGTCC 2040
GTTCTTGAGAAAGTGGCCTGAGATTTCTCACTTGGTGAGAAAAAGGACGGCGAGCGGGAG 2100
CCTGAGTCAGAAATAACCTGTCTCCTTGGATCTCACATGACGGTGTGTGTGGAAGAGTG 2160
CATCTATTGTCATTGCTGGAGTGACGGCAGAGTAGGGTCTAAAGAAACCCATACTAGT 2220
AGAGATGGAGAAGACAAACAAAGCCCAAGACGACAGACGACAGAAGATTAAAGCTATC 2280
AGAGCGAGACTATATCACTATTTCGAAACCTGCGAGTAATTTAACAAGAAGTACACATCAT 2340
CATGTGTATCAATTTCGACGAAGACATGGTCGAAAATTTCTGCGGTGTATATGTCTGTTGT 2400
ATATGGGCCCTGGGCATTGTTATTTTTCGCCGTCTTTATGTGTACTAACACTTCCATTGAT 2460
ACCCAGAACAAAGATGAACGCTTAAACAGCACCAACAAATCAGGAGAAGAAATGGCGCTGC 2520
TCTAGGTATGCTTCTGGGATAAAAGCGATGTTGTATACCTCTCAGAAAAGAAGTATTG 2580
AAGTTGAATCAAAACAAATAGCCGATGGAGCGATCTGAAGGGTGGCAGACCTGCTACGCG 2640
CATTTAGGCAAGGCATCAACTCGGCAGATGATTAAGAAAGGTTTGTAGGTTTCACGTGTT 2700
GTGTTGTGTTCCATTATAAGTTTATAACCTTGCTAAGATGCAACGACTCTGACCTCAGGG 2760
TGTTAGAAAAAATTGACCACTAGGAGCATAAGTGACGAAATTCGGGGATCAAGACAAATAGA 2820
TAGTTTCATTTTCATGTGCTCCTACGTCTTTTTCACGTAATGTGTTTCTTATAAAAAAAGA 2880

Fig. 1B

TAGCATGTCTCTTTGGTGAAGAGAAAAAGATGTTACGACGTGGCCTTGATTCGAA 2940
CAGACGCCCTCCGAAGAGAAATAGATTCTAGTCTATCGCGTTAGACCACTCCGCCACCACG 3000
CCTTACGTAATCTGTGATTGTTGAAGTTACTCTCGTGTACGGTCTATACGTGAAGAAT 3060
CTACACTTGACGAGTCTCGAGGTCCTGGGTCAGTTAGACGGAAATGGGAGAACAAAGAGA 3120
CTTGGTGACATTGCAGGCAACCGGTAGATGTTGAGGTCAATTGATCGGACAAGATTGTTG 3180
CTTCAAAAGTAAACAGGTATTCTTTTTTTTAAATCAACAGAAACGTTCCATGTTCAATTGTT 3240
AATCCAATCTATTGTGATAGCGTTTGATGACAAACAATAATAATGATGGCTGGCGGCT 3300
AGTGATCGTTTGTAATGACGTCGTCATATATCCTATCACTATACAGTTGCTTTGCACACG 3360
CACTCACGTCCTTCATTCTGTTCTTCACTATTGATGGTGATTGTTCAACAACCTAC 3420
AGAAATAATGACCTGTGGTGTCTCCGAATATGGCTAGACCAACAAGCTTGTAACCGG 3480
GCATTCAAATCACCATGTGATGCCCATCATCAGATCATCCACCACCAAAACAGACCA 3540
ACTACTCACAAAAGGCATCTCATCAAGAAAAACGGCCAATAACGTCCAAAGGCCCG 3600
AAAAACGTCATCACGCCCGAGACTTCAATAGACTGCACAAGAGGCCGATGAG 3660
ATCGACCAGACTAAACCCGGGAGAGTGTCAAATATCGGGGGGATTGGGAACTTACCCCA 3720
GAAAGAGAGAGGAGATAAATTCATGTCTGGGTTGACGTCCTCTATTGTTAGACACGA 3780
ACGCCTGCTCTCGGCGTAATTTATACCATAGCGCCAATGAGGGCGGAAACTCCTGTTTG 3840
TCAAGTCGTCATTGTTGGTTCATGATATATAGCCAGTAGGTATCCGTCCTTGGTGAT 3900
TGACCAGACATATCGCTCATCACAGATCAACATCACTGCTATCACCAACATGCTTACTCA 3960

M L T Q

AGTCCTTTATGGCTTGGTAGCCAGTGCCCTTTGGCAAGGCCAAGTCGTTGTCATCACCAAG 4020
V L Y G L V A S A L W Q G Q V V A S P S
CAAGGACAATTCACTGGAGCGCTTCATTGACAAACAAGCTGATATTCTATCAAGGGTGT 4080
K D N S L E R F I D K Q A D I S I K G V
CCTTGCTAATATTGGCGCTGATGGAAAAAGGGCACAGGGTGCAGCGCCTGGTGCTGTTGT 4140
L A N I G A D G K R A Q G A A P G A V V

Fig. 1C

4/24

GGCAAGTCCATCGAAAGAATCTGATTgtaagccagcatcctaccttgctccttgccg 4200
A S P S K E D P D
catgctaataatgatggtctcagATTGGTACACTTGGTACACTTGGACTCGTGACTCTGCTTTAACGTACAA 4260
Y W Y T W T R D S A L T Y K
AGTGCTCGTTGAGAGATTATCCACGGCGACAAATCTCTCCAACGAAAGATAGATGAATA 4320
V L V E R F I H G D K S L Q R K I D E Y
TGCTCTCCGACACAAGCGAAACTGCAAGGACCAACAATCCATCGGGCAGCCAGAGTCGGG 4380
V S A Q A K L Q G T T N P S G S P E S G
CGGTCTCGGCGAGCCAAAGTTCCATGTGAATCTCACTGCTTTCACTGGATCTTGGGGTCG 4440
G L G E P K F H V N L T A F T G S W G R
GCCTCAGCGGACGGCCCTCCGCTTCGGGCTACCGCCTTGACTCTGTATGCAGAATGGCT 4500
P Q R D G P P L R A T A L T L Y A E W L
CATTTCCACGGGAAAGATCCAAGGCTTTGAACAAGTCTGGCCAGTCATCGAGAAGGA 4560
I S H G E R S K A L N K V W P V I E K D
CCTTGCGTATACTACCAAGTTCTGGAATCGCACTGGCTATGATCTATGGAGGAGGTAA 4620
L A Y T T K F W N R T G Y D L W E E V N
TGGATCTTCTTTTACACTTTTCGGCTTCGCATCGTGCTCTTGTCGAAGTGCCGCTCT 4680
G S S F F T L S A S H R A L V E G A A L
GGCTAAGAAACTTGGCAAATCTTGTCTGACTGTGTCAACCAACGCTCCTCGGTTCTGTG 4740
A K K L G K S C P D C V T N A P R V L C
CTTCCTTCAGACTTTCTGGACTGGTGCTACGTTGACTCCAACATTAACTCAAGGATGG 4800
F L Q T F W T G G Y V D S N I N V K D G
TCGCAAGGTCGATGTCAACTCCATCCTCTCGTCCATTATACATTCGATCCCAACTC 4860
R K G L D V N S I L S S I H T F D P N S

Fig. 1D

5/24

CAAGTGACCGACTCGACGTTCCAGCCTTGTTCAACCAGAGCTCTTGCGAACCAAGGC 4920
K C T D S T F Q P C S P R A L A N H K A
GGTCGTCGATTCTTTCAGGTCAATCTATGGTGTCAACAAGAAATAGAGGTCAAGGCAAGGC 4980
V V D S F R S I Y G V N K N R G Q G K A
CGCGGCTGTTGGTCGATATAGCGAGGACGTGTACTATGATGGCAACCCTTGGTACCTGGC 5040
A A V G R Y S E D V Y Y D G N P W Y L A
CACTCTTGCTGTCAGAACTCTACGCTGCGGTCTACCAGTGGGATAAGCTTGCGC 5100
T L A A A E Q L Y A A V Y Q W D K L G A
TGTTACTGTTGACGATGTATCTTTGTCTTTCTTCAAGGATATCGTTCCCAAGGTCTCCAA 5160
V T V D D V S L S F F K D I V P K V S K
AGGCACTTATGCCAAGAACCAAGACATACAAGAGATCATCAAGCAGCCCAAGACTTA 5220
G T Y A K K T K T Y K E I I K A A K T Y
CGCCGACGGCTTTGTGCTGTCGTCAGACATACACTCCCAAGGACGGCTCACTAGTGA 5280
A D G F V A V V Q T Y T P K D G S L A E
GCAATTGACAAGTCAACTGGAGCCCCCAAGTCCGCTGTTCACCTCACCTGGTCCTACGC 5340
Q F D K S T G A P K S A V H L T W S Y A
CGCCTTTGTGCGCCACAACCTGAACGTGCGACGGCATCATCTCTCCCTCCTGGGCGAAAG 5400
A F V A T T E R R D G I I S P S W G E S
CAGCGCCACAAGTCCCCGCGTGTGTCAAGCTGCCCGCATGTGACACCAACCATCAC 5460
S A N K V P A V C Q A A P A C D T T I T
CTTCAGTGTCAAGAACGTGCAAGTTTCATCCGACCAAAAGTTTACGTGGTTGGCTCAGT 5520
F S V K N V Q V S S D Q K V Y V G S V
GACTGAGCTTTCTAACTGGTCACCTGATGATGGCATTGGCGTTACGCCATCTAGTTCCGG 5580
T E L S N W S P D D G I A L T P S S G

Fig. 1E

6/24

AGTGTGGAGCGTCAAGGTTAAGATTCCTTCTGATACAAGCTTTGAGTACAAGTATATCAA 5640
V W S V K V K I P S D T S F E Y K Y I K
GAAGACTAGCAGTGGGGATGTTACGTGGTTGAGTGATCCCAACAACCGGCTATTACGGG 5700
K T S S G D V T W L S D P N N R A I T G
TAGCAAGTGTGGAAGTACAAGTACTCTTGATGATGAGTGGAGGTAGTGGATGACAGATTT 5760
S K C G S T S T L D D E W R .
ATCAAGCTATGTAGTTTGTGAATATAATAATATCCAAATTATCAGGGTTCGGTAAGAAT 5820
ATAATTCAAGTTCAGCAGTCTGTACAAGCAAGCCATGATTCACGCTTCCTTCGTTTGAAG 5880
ATAAGGTTCCCTCGCCACCGTCAAGATAATTTCTCGTGCTAATATCACGTAATCCATCT 5940
GCATTAAACCCCTTGCCGGGAAGGTTTCTTCAACCCAGCAACCCAGAGTAACTCGGAGAT 6000
AGGGAAGTCTATTTGCCCCTTATCCCTCCGTGACGAATTCCCTGAACCCAATT 6050

Fig. 1F

SUBSTITUTE SHEET (RULE 26)

7/24

AATTACTGTGTGATCAGACCTAACTAAATACCTAACCCGATGGATCGACA 60
AGGAAATCTCAGCCCTTGTGAGTCTCCTCTTTCGTCTGTCTCCTGGCTCGCTACTGT 120
CCGATTGTAACCTCTCGCTCTCCAACCTTGTTCAACTCTAATAAGTGGTGCACACGTGAA 180
GATGTAATTGTTGTGAGCGGGGGTTCGGTGGCATTACCAAAGAGACCAAAAGTCCCC 240
CTATGTCGATTGATGGTGTGCGTTGCCATGATACGGGACCCCGAATATGTTGTATGCA 300
TCATGCGTACAGAAAGCTACTGTTCAAAACGAACGGCAAGCGGATTGATCAACCCGTGA 360
AAGACCATGGGTCTCTCAGTCCACAAATCTTCTCTTCCTGATCAAAATTTATGGATCCAA 420
GGGCCACAATTCTAGCGCCATCATGGTCCCTTTCCTCTTTTCGCTCACCCCATGTTCC 480
CTGTCCCACCTCATTCAGTGGACCTGATGGATCCCTATCCCCCGATGAGCCGGGGGTGC 540
AGCCTTGGCGCTCTCTTCTTGTAGTGTGACCTACTGTTGATTTCACTCAGCAGTCCTAG 600
AGTCCATTTAGTTGGCCCTGGGTGATGGGTCTGAGACTTGTCTTCTTGCTGCTGCTTG 660
TCTAGCTCGAATCTGTGGGTTCGCCCTGGCCTGGCCTGACCTGACCTGAGGGGGTG 720
CCCCTTTGCTCTGTTCTGCATATGTTGCTATTAGCTACCTACTCGAGAAATTCATAAAGG 780
ACTGTCCAGCCCCGTCTCTACTGACTTCTTTCCTTTCCCTCTTCACCCCTCGTTGCATA 840
TCAAATCTGTCACTCGTTAGACCAGACTACCAATTCACACTTTCGCTTTTAAACTACTTTA 900
CTCAACTAATTCTAATACCAACTCCAAAACCATCAACATGCGTTTCACATCAATCCTCG 960

M R F T S I L
CTGCCGGCGCTTTTCGCCACCATGGCCGCTGCCAGAGCAAGACCGTCTCCCTCGACCCCTG 1020
A A G A F A T M A A A Q S K T V S L D P
CTCAGCAGTCTCAGGCCGACTGCCCTCTCCGACTGTGAGCCTGGCGATGTCAAGTGCCAGT 1080
A Q Q S Q A D C L S D C E P G D V K C Q
CTTACTGCATCACTgtatgttacaacaacgattccccctgtcatgtgtagaaactaaaca 1140
S Y C I T
tcccaatagGTTCCCTCTCCTGACGAGAAGAACATCGAGGAACCAACCAAGTGTGTTG 1200
V P S P D E K N I E E T T K C C L

Fig. 2A

8/24

CCGCCTGCCCAAGGCAAGGCTCCGAAGGCCGACACTGAGAAAGTACACCGTTTGCA TG 1260
 P P A P R A R A P K A D T E K Y T V C M
 AACGAGTGATCGCCGACAAC TACTGGAAGTCCGTTGATGGTACCCCGTGACCCGAC 1320
 N E C I A D N Y W K S V D G T P R G T D
 GTCCCGATGTCAAGAGCAAGGCTCCGAGGCTGCCTCCTCCGCTGCTGAGAAAGGCCACC 1380
 V P D V K S K A S E A A S S A A E K A T
 GCCACCGGTACTGCTGAGTCTGATGCTACCGCCACTGGTGCTCCGCTACTGAGTCC 1440
 A T G T A A E S D A T A T G A S A T E S
 GAGTCCGGCTCCGACTCCAGCTCCGAGGAGACCGGCTCTGCCCTCTGGCACTGCCACTGGT 1500
 E S G S D S S S E E T G S A S G T A T G
 ACCGCTGCTGAGGTCTCCGAGACTGGTAACGCCGCTCTTCCCTCGTTGGTGTCTCC 1560
 T A A E V S E T G N A A S S L V G G V S
 TTCCTCGGTCTCGTTGCCGCTATCTTCGCTCTGTAAATTGGGTTTCCTGCTTTAGGATAA 1620
 F L G L V A A I F A L
 TCTGATTTGGCATGACGGAGAAGGATTTAATGGGTTTATTACAGCGGTAATGATTGGAG 1680
 TTTGGATTTCAAGATGTGACACGTTGGACAGCATGATAAGGCCCTACGGGCTGATCAATT 1740
 TCATGGACAAATTTTGTTT TTTGGGTAATCATTTTCGCGTTTACATATGGCTCGGCATAT 1800
 GAGCATGAATACAATACCTCTTTTTCGCCCTCAATTCATTCCTTCTTGATCTCA 1860
 CAGTGATTCAACTTACAAGTTGCGGCGGACCACTGAGGTCGTCTGATGTGGGTCTTC 1920
 TGTTTGATTTGGCTCATGATTCCCAATCGGGTCTTCAAACGTTAGTTTGTAACAAGC 1980
 GAAATGAGGCTCTTAGGATGCATGTTCAAAGCGCAAAACCCAATTGAATTCAAATGTTAA 2040
 AGAATCATCGAGAAGAGCGAGTTACTGAGGTGAATTTGTGCTTTTCAACTGTCAATACCTC 2100
 CCTCAGAACAAATGAATTGAATTATTATTCACACTCAATGCCCAATATTCTAAACATGTT 2160
 CGTTGTAACAGAGTTTAAATTCCTTGACGCCACAATGTTCTTGGTAATTATCGCGCCTG 2220
 TCACATGAAC TGGCTCCTGAACTTAAACGTTGGTGACCCAGCAACTCGTTTATCAGGCTT 2280

Fig. 2B

9/24

AGGGTAGCTGTCATACAACAACAACTTGTACAAATTGATGTTATTGATGAAATCATATAT 2340
AGAAGAGCACAAATTGATTTAAACACAGATAAACTGGTCGAACCGATTTTATCAGGTTGTG 2400
TGAACATGCATTGCCGAATCAGAAACCCAGAGTAAGACTATCTACAGTTCCATGAAAGACAA 2460
TTCACAGACTGCCAGAAAGCAAGGTACTGGAAGCACGAGAGACAAATTTATTTGAATT 2517

Fig. 2C

10/24

AATTAGAGGTTAGGATTTCACATGGCCACCACATGGGAAGGAGGCAACCATCTGCACG 60
AGCCACCAAGTCATCTCCTCAAACTGTGCTGCGACTAAGAAATTGATTCGGTTCTGGC 120
CTGGCCTTTGTATCAGCTAGGTCAATTCGACTACCGGAGGCCAGGCTGAAGCAGTCAGT 180
CACGCAATTGTCACTTTATCGGTCCTGTCTCATACGGATACACTAGGCGTCAATGGGCTT 240
CAAACGGAGATCCAGAGATCTCATGAAGAGCATCGACGATAAAGTGAGTGGTGGGGATA 300
CTGTGCGGTGCCGACCCAGCGGAGCCAGGTTCCACCCTTGATTACATGGTTGAAAGT 360
GGCGTTACTGCGGAGATCAAAATTTGGCATGTATGTTCCGTCCAATGACGCGAGCTCTCCA 420
TGTGCTGCCGAGGTCAGGAACGGACCAAGCATGGGATCAGTGAGGTGAAATCCAACCGAG 480
GGAGAGCGAGATCTTTGTGCTCATATCCATGCTGCCATGCTACGTGCCGAACAGGCCAGA 540
TGGCGTTCAACTCAGTCGACCAAGGTCGATGAACGCGGAGCGGTGACGAGATCGAAGCTT 600
CATCTATCGCTTACGGGTTATGTTCCACTTTCCATTAAACGTTTGCGAGTTGCTGTTTGA 660
GAGCCATGTCGAAAGCATGGACCGGTGTCACATCTTTCAAGGTAAATCTGGAGGTGGGAAG 720
AAGAAATTGCGAGGAACAGGATGGGAGGATAGCAGGCTGACGCGGAAAGCTAGGTAGCTAC 780
CTGGCTGATTACTGGCTAAAGCTGGAGAGCAACTAGGTAATATCAGGCAAGAGCTCCAA 840
GAGCTATTGGAGGCTGGCTGATTGCTCTGCTGAGACGCGAGGAGGAGGTTAAATG 900
GCCGGCAGGCCAAGAAGGGCTGCAAAACACGGAGTGATGGTGGGCCCTCCACATACG 960
GGATTCCGGCTGCGGATCTAACCTCAATTTGGCAAGAGGTAAATAGGACGACATGCAGGC 1020
CCCCTGACATGTAAACAAGACAAGTGGTAACAAGCCATCAACATCAACAAGAGCGAACA 1080
ATCGACACACCCATGGGGTGAGATATGGTAGTAAGGCAGAGAGAGATCAGGGCAGCATA 1140
CGTGGGAAAGGGCTGGGCAAGAAAGGACACAAACGGATCAACAGAACCGCAGCGCTACCGAG 1200
GGAGCAACACAAGTACAGTAACCGCTCACAGAGGCACAACCTCGTCCAATCCTGCCCCCGT 1260
CTTCAAAAGCCAGTTTCGTTCTGAGTCCTGTCCGTCCCTCTTCTCCTCCTACTCCCTC 1320
CAATTATCGCCATCCACATCGACATCGTCAATTACAAACCTCACCCAGACAGAAGAAAA 1380
GAACGACTGAAGGCCTTCGCTCGCCATCACCCGATTCTTTTCCATTCTCTTCGACTTTTG 1440
TTTCGTAGGAACAAGAGCCAGAGAACTTCTTGTCATCCCTTTCGAAATTTTCGGAAGTTGTA 1500

Fig. 3A

11/24

TGAGAAAGCTTCTCGCGCCAGCAAAGTCGCAAAATCTGGAATTTGAGGCACGCGTCCCC 1560
GTTCCCTTCAGCATCTTCCCATCGACATATCGGGAATCCGAATCCACACACAGACCGTT 1620
ACCGAAACAAGATACACGAAGAGGTTGAGATCAAAACCCCAACAGCCCGAAGCCGGACGG 1680
GAAGGTGAAATATCTTCTGTCTCCGTCAACCGCCGAACAGGTCCCTCCTCCTCGTCAAGAG 1740
CAAGAGTTTATCGAAGAAGAGGTCCATATTACGCGTGAAGAAGAACATTACCACCGTCCC 1800
GGTGTCAAAATTCGAGCACGAAGACTTTTACTATCCGTGAAGACTCCGACGGtacgtt 1860
cgattttacatttcctttcatctccatttaggtcgcatcttttctggtactttttggtc 1920
aattacacggggatacgaattttccacggtcggagaaagccctgcttgctctctatgcc 1980
taggtctgtattctcatccctctgcgctgatctggccatggagacgtgtgagaacaag 2040
actacaattcatcacatcattttcgctaggcgaaagcaattaccggtgtccccgacctt 2100
ctcccaaccatcagttttcactttcccttttcttggtctggcttgcccttgaccattaccc 2160
accgcgacggagcgcttcagtcgccagccatcccatctcatcacttctcatatcct 2220
ctcttcacacgcctcacacacccccctgcctgctaccatgccaaaccacttcagctt 2280
ggctggatacccaatttgctttgcttcctcccggtcactagcgcctctaaagcctgtg 2340
gcctgagcaaggcgtggagctatctcaggggcccgcctccggtggccatatgatacg 2400
caacgacttactatagacatccatcagctaaccacagacaaatctagACCTCAACCTCCC 2460
TCTCAATACCAACCTTCCCAGTACCACCAACCTTCCCACCTACCAACCACTCCCAATTC 2520
CAAACCTTCTCACACTCACGTAGAGATCGACACCCACCGTCACTCCCTACTCTCACCCCC 2580
ATTGATCTCGCTGAACGTGAATACCGCCAGCGTTACCGCCCTGCCCAAGCTTTTCCACA 2640
GAAGACCCCTTCTTCCCACCTCTCATCTCTCACTACCAACCTCAAGACAACCTTCAAGCCAAC 2700
AACTACACCGTTGAAGCCGACCCGCTCCCAATTCCATTCTCTGAGAAGACTGAAATC 2760
AACAAAGTTTACTGTTGACGAACACTCCTCTCGCCCTCAGTACAACCAACCGAGAAGACC 2820
GAATTCAACAACACTACACTGTTGACAGCCGATCTTCCCGTCCCTCAATACAACACCTGTGAG 2880
AAGACTGAGATCAACAATTCTACTGTTGACGCCCGCTCTTCCAGCCACGGTACCGGAC 2940
ACCAAGACAACCTCAAGTCAACAGCTACGCCGTTGACAAGCCCGTTTCTCGTCCATCTTAC 3000

Fig. 3B

12/24

AAGAAGGACGTGAGATTACTGAACAAACCGTCGAAGCTTCAAAGTCCGACAAGTCCAAAG 3060
ATGGGTTACTACGACGACGAGGgtaagtgaatctgtcaccacgagagagccatcgaact 3120
M G Y Y D D E
ctctattcgtgacgcaattcaagctaaccacagtcaccagGTTCTTTCCGAAAGGAGGAA 3180
G S F R N G G
TCCACAAGCTCGGTGACAAGTCCCGGACATTGAGGTTGACATTCGGCGAGACATTCTCGTC 3240
I H K L G D K S R D I E V D I R E T S R
CTGCCAATGACTGCGCTCCCAACACCGTCAGCATCCCCTGCCACACATCCGTCTGGGTG 3300
P A N D C A P N T V S I P C H H I R L G
ATTTCCCTCATGCTCCAGGGCCGCCCTGCCAGGTATCCGCATCTCCACCTCCTCTGCCA 3360
D F L M L Q G R P C Q V I R I S T S S A
CTGGCCAGTACCGCTACCTTGGTGTGCGACCTCTTCAACCAAGCAGTTCATGAGGAGTCTT 3420
T G Q Y R Y L G V D L F T K Q L H E E S
CTTTCATCTCCAACCCCTGCCCCAGCGTTGTCGTTCAGTCCATGTCGGCCCTGTCTTCA 3480
S F I S N P A P S V V V Q S M L G P V F
AGCAGTACCGTGTCTCGATATGCAGGAGGTGAGATCGTTGCCATGACCGAGACTGGCG 3540
K Q Y R V L D M Q E G Q I V A M T E T G
ACGTCAAGCAGGGTCTCCCTGTGATGACCAAGTCCAACCTCTACTCTCGCCTCCACAACG 3600
D V K Q G L P V I D Q S N L Y S R L H N
CTTTCGAGTCCGGTCTGCTGTTCGCGTCCCTCGTCCCTCAACGACGGTGGCCGTGAGC 3660
A F E S G R G S V R V L V L N D G G R E
TTGCCGTTGACATGAAGGTATCCACGGCTCTCGCCCTGTAAAGCGTGTCAACTGTTTCT 3720
L A V D M K V I H G S R L
GAATTGGGCAGCCGCTTGCAATGCGACTTCTTCCCAATGTTTAATTGAGTGAAGGACA 3780
GCACTACCACTCTCACCTCAACTGTGGGAGCGGGTCTGGGCTGTCTCTAATCTTACCTG 3840

Fig. 3C

13/24

TACAAATGTC AAGTTTCATAGGGGACCTGTTGTGTCAAGATGGTTCGAGTTTGTGTGT 3900
CAAGATTGGATAAATGATATTGGCTAGCTGGAAATACTGGAGTCTTTTGTGTAGATGGGA 3960
GAGTTCTGTACATGAACCTATAGTAATTGACAATTGATTCGCCATCTACTTAGCTTTTCAT 4020
TGGTGCTCTATGCCCCAACATGTGAATT 4047

Fig. 3D

14/24




Fig. 4

15/24




Fig. 5

16/24




Fig. 6

17/24




Fig. 7

18/24




Fig. 8




Fig. 9

20/24




Fig. 10

21/24




Fig. 11

22/24




Fig. 12

23/24




Fig. 13

24/24




Fig. 14

SEQUENCE LISTING

<110> Randy M. Berka
Michael W. Rey
Kimberly Brown

<120> Promoters For Expressing Genes In A
Fungal Cell

<130> 5611.204-WO

<140> To Be Assigned

<141> 2000-03-22

<150> 09/274,449

<151> 1999-03-22

<160> 40

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 6050.

<212> DNA

<213> Fusarium

<400> 1

aatttcgctcg	atagcgaggg	actcctggcc	ctcgaattta	gttagcggtat	cagtgtaaag	60
tgctgggttc	tccaggcgta	agtaaattga	accagatggt	agctcccaga	tttcgccccg	120
aagccggttg	ggcagaccaa	cgcggataag	tttatggaaa	gttgggtggc	ggatcaatgt	180
aaagttcctg	ccattgtcac	gcagatactc	ggcccaaaga	cgcattcttg	ccctatcgcg	240
caactttttt	gggtccccag	gatatacgga	gagcattcct	aagccagcat	ctgggtgggag	300
atcggttcttc	ttatcttcgg	ttcttaaaaag	atgttcagag	taacactcag	cagcaactcg	360
acgcaacttg	gctacgttgc	caacgcctgc	tctaagaccc	ttcttgaggc	cgtcacagaa	420
acgttcgcag	gactgtctgg	ttccagcgag	atggattggt	atgcgttggt	ctcggggggtc	480
tctcttggtct	ttagaggtat	cggcaagaag	gccattccac	gtagtcagag	cgagtgcgaa	540
ctataaccag	gcaacgtcag	aatttggtacc	atgcaagatt	tttataccac	atacctggaa	600
gttctggcta	ttcaagcgct	ctacccttcg	tatagcacat	aaaggaaatg	tgaatccatt	660
gccactgggt	cctcctccgt	gtgtctggcc	ggtaaaagcg	gtcgagggtg	aaaggctagc	720
agattgcaca	aagctagtgg	gtgttggtga	gaagcacatg	taatgctctg	acaggtgtag	780
cttgccagca	taatgccatc	ctcgatcggt	atccttatca	ccgtgagtag	cggtggaggg	840
cgggatagta	agctcggcgt	tgatctcgta	gaggggagcg	tgagaggcgg	gcaagcgaaa	900
ttggctctga	aatagcgatg	actttgaggg	attccgatct	gaactggata	gattgagccc	960
ctgggtagga	tcgataagct	gctgggcttt	ttgaacgatg	ttgggtgaagt	tcgaaaacat	1020
gatttcgggtc	agcggcgcgt	gacgaggggg	gttccgggtcc	aggagggagg	tcgcggctga	1080
gcttgaagga	gatgcaagac	acgaagcgaa	agacacgaag	agagcgcaag	agtctgagta	1140
tgtgcaacca	ggctcgaata	agtgaaggc	aggcagaagt	acggaataga	cgatagaatt	1200
gagtatagaa	aggctgaatg	gaagatggag	acgagttata	ggacgggtga	gatagagtgg	1260
agttgaagtt	gaacgaagct	gcgtcagggtc	cagatacggg	agactggcca	tcaactactg	1320
gccaggtagc	cagggcgcga	tgggcgggtg	ggcaggggtcg	cggggggggac	ctcagggcat	1380
tcctttctcc	aagggccgct	ggggctatgg	acggggctgg	ctgaactcca	gccgtcatgg	1440
gatagcgggtg	caagagatca	ggtactaagt	ctaccatgat	aatttagggg	gcagagaaaa	1500
atgatataatt	tgttttagtag	taagcgggtt	tttacagttg	aggaaccaac	cttcttcatt	1560
tattttattct	ttctttctct	gcaattcagt	cctttttctt	aaatagaata	tctaccaatg	1620
gaacggcgtg	gctgaagtgg	ctgaagaata	tagctcgagc	tgtcaaaccg	ctcatcctac	1680
taccctaggt	ataaagctgg	gaactaagac	tcatttctat	ccaactcatc	atattgggag	1740
ttagtgtaga	cctgtcggcc	tagagaatat	gtgtatctgc	atactttcaa	ataccctacg	1800
tataccact	atgttttagca	caatcattga	cctctcaagg	cctcaccat	ctcaaacact	1860
gtcgtgtgct	cacttgacta	cttctttgaa	ccagctcgcc	atcggactag	tcgaacaagc	1920

ttgtcgcccc	catacagatg	aatgtatggt	taaagctaca	tgatcagcct	gaaccgagca	1980
taactcgagt	gccgagactc	ctctgatgta	tatcgagatg	aatgacaaac	ctacgggtcc	2040
gttcttgaga	agtggcctga	gattttctcac	ttggtgagaa	aaaggacggg	cgagcgggag	2100
cctgagtcag	aagaaatacc	tgtctccttg	gatctcacat	gacggtgttg	tggaagagtg	2160
catctattgt	cattgctgga	gtgacggcag	agtaggggtc	taaagaaacc	catactgagt	2220
agagatggag	aagacaacaa	aagcccaaga	cgacagagac	gacagaagat	taaagctatc	2280
agagcgagac	tatatcacta	ttcgaaacct	gcgagtaatt	taacaagaag	tacacatcat	2340
cattgttata	aattcgacga	agacatgggtc	gaaaattctt	gcggtgtata	tgtctgttgt	2400
atatgggcct	gggcattgtt	atTTTTcgcc	gtctttatgt	gtactaacac	ttccattgat	2460
accccagaac	aaaagatgaa	cgcttaaaca	gcaccaaata	caggagaaga	atggcgctgc	2520
tctaggtatg	cttctgggat	aaaaagcgat	gttgatacct	ctcagaaaag	aagtgatttg	2580
aagttgaatc	aaacaaatag	ccgatggagc	gatctgaagg	ggtggcagac	ctgctacgcg	2640
catttaggca	aggcatcaac	tcggcagatg	attaagaaag	gttttgtagg	ttcacgtgtt	2700
gtgttggtgt	ccattataag	tttataacct	tgctaagatg	caacgactct	gacctcaggg	2760
tgtagaaaa	attgaccact	aggagcataa	gtgacgaaat	tcggggatca	agacaataga	2820
tagtttcatt	ttcatgtgct	cctacgtctt	ttcacgtaat	gtttcttata	aaaaaaaaaga	2880
tagcattgtc	tctttgggtga	aaagagaaaa	aaagatgtta	cgacgtggcc	ttgattcgaa	2940
cagacgcctc	cgaagagaaat	agatttctag	tctatcgctg	tagaccactc	cgccaccacg	3000
ccttacgtaa	tctgtgattg	ttgaaagtta	ctctcgtgtt	acggtctata	cgtgaagaat	3060
ctacacttga	cgagtctcga	ggctctgggg	cagttagacg	gaaatgggag	aacaaagaga	3120
cttggtgaca	ttgcaggcaa	ccgggtagat	gttgaggtca	ttgatcggac	aagattgttg	3180
cttcaaaagt	aacaggtatt	ctttttttta	atcaacagaa	acgttccatg	ttcatttgtt	3240
aatccaatct	atTTgtgata	gcgtttgatg	acaacaata	ataatgatgg	tctggcggtc	3300
agtgatcggt	tgtaatgacg	tcgtcatata	tcctatcact	atacagttgc	tttgacacag	3360
cactcacgtc	cttcattcgt	tgtcttctact	atTTgatgg	gatttggttc	aacaacctac	3420
agaaataatg	acctgtgggtg	ttctccgaat	atggctagac	caacacaagc	ttgtaccgcg	3480
gcattcaaat	caccatgtga	tgcccatcat	cagatcatcc	accaacccaa	aaacagacca	3540
actactcaca	aaaaggcatc	tcatacaagaa	aaaacggcca	actaacgtcc	aaaaggcccg	3600
aaaaacgtcc	atcacgccgc	agccgagact	tcaatagact	gcacaagaag	gaccgatgag	3660
atcgaccaga	ctaaacccgg	gagagtgtca	aatatgcggg	ggattgggga	acttacccca	3720
gaaaagagaa	ggaggataaa	ttccatgtct	ggggttgacg	tctctatttg	ttagacacga	3780
acgcctgctc	tcggcgtaat	ttataccata	gcgccaatga	gggcggaaac	tcctgttttg	3840
tcaagtcgtc	attgttggtt	gggtcatgat	atatagccag	taggtatccg	tcttggtgat	3900
tgaccagaca	tatcgctcat	cacagatcaa	catcactgct	atcaccaaca	tgcttactca	3960
agtcctttat	ggcttggtag	ccagtgcctt	ttggcaaggc	caagtcgttg	catcaccaag	4020
caaggacaat	tactggagc	gcttcattga	caaacaagct	gatatttcta	tcaagggtgt	4080
ccttgctaata	attggcgctg	atggaaaaag	ggcacagggt	gcagcgccctg	gtgctgttgt	4140
ggcaagtcca	tcgaaagaag	atcctgattg	taagccagca	tcctaccttg	tccttgctcg	4200
catgctaata	atgggtctcag	attggtacac	ttggactcgt	gactctgctt	taacgtacaa	4260
agtgtcgtt	gagagattca	tccacggcga	caaatctctc	caacgaaaga	tagatgaata	4320
tgtctccgca	caagcgaaac	tgcaaggagc	cacaaatcca	tcgggcagcc	cagagtcggg	4380
cggctctcggc	gagccaaagt	tccatgtgaa	tctcactgct	ttcactggat	cttgggggtcg	4440
gcctcagcgc	gacggccctc	cgcttcgggc	taccgccttg	actctgtatg	cagaatggct	4500
catttcccac	ggcgaaagat	ccaaggcttt	gaacaaagtc	tgggcagtc	tcgagaaggga	4560
ccttgcgat	actaccaagt	tctggaatcg	cactggctat	gatctatggg	aggaggttaa	4620
tggtatcttct	ttctttacac	tttcggcttc	gcactcgtgct	cttgctgaag	gtgccgctct	4680
ggctaagaaa	cttggaacaa	cttgctcctga	ctgtgtcacc	aacgctcctc	gcgttctgtg	4740
cttccttcag	actttctgga	ctgggtggcta	cggtgactcc	aacattaacg	tcaaggatgg	4800
tcgcaagggt	ctcgatgtca	actccatcct	ctcgctccatt	catacattcg	atcccaactc	4860
caagtgcacc	gactcgacgt	tccagccttg	ttcacccaga	gctcttgcca	accacaaggc	4920
ggctcgtcgat	tctttcaggt	caatctatgg	tgtcaacaag	aatagagggtc	aaggcaaggc	4980
cgcggctgtt	ggtcgatata	gcgaggacgt	gtactatgat	ggcaaccctt	ggtacctggc	5040
cactcttgct	gctgcagaac	aactctacgc	tgcggtctac	cagtgggata	agcttggcgc	5100
tgttactgtt	gacgatgtat	ctttgtcttt	cttcaaggat	atcgttccca	aggtctccaa	5160
aggcaacttat	gccaagaaga	ccaagacata	caaggagatc	atcaaagcag	ccaagactta	5220
cgccgacggc	tttgctcgtg	tcgtgcagac	atacactccc	aaggacggct	cactagctga	5280
gcaatttgac	aagtcaactg	gagcccccaa	gtccgctgtt	cacctcacct	ggtcctacgc	5340
cgcctttgtc	gccacaactg	aacgtcgcca	cggcatcatc	tctccctcct	ggggcgaaag	5400
cagcgccaac	aaggtecccc	ccgtgtgtca	agctgcccc	gcattgtgaca	caaccatcac	5460
cttcagtgtc	aagaacgtgc	aagtttcatc	cgaccaaag	gtttacgtgg	ttggctcagt	5520

```

gactgagctt tctaactggt cacctgatga tggcattgcg cttacgccat ctagttccgg 5580
agtgtggagc gtcaagggtta agattccttc tgatacaagc tttgagtaca agtatatcaa 5640
gaagactagc agtgggggatg ttacgtgggtt gagtgatccc aacaaccggg ctattacggg 5700
tagcaagtgt ggaagtacaa gtactcttga tgatgagtgg aggtagtgga tgacagattt 5760
atcaagctat gtagttttgt gaatarataa ttatccaaat tatcagggtt cggtaagaat 5820
ataattcagt tcagcagtct gtacaagcaa gccatgattc acgcttcctt cgtttggaag 5880
ataagggttc ctcgccaccg tcaagataat tttctcgtgc taatatcacg taatccatct 5940
gcattaaacc cttgccggga aggtttcttc aaccagcaa cccagagta actcggagat 6000
agggaagtct atttgcctta tcctccgtga cgaattccct gaaccaatt 6050

```

<210> 2
 <211> 200
 <212> PRT
 <213> Fusarium

<400> 2

```

Met Arg Phe Thr Ser Ile Leu Ala Ala Gly Ala Phe Ala Thr Met Ala
1      5      10      15
Ala Ala Gln Ser Lys Thr Val Ser Leu Asp Pro Ala Gln Gln Ser Gln
20      25      30
Ala Asp Cys Leu Ser Asp Cys Glu Pro Gly Asp Val Lys Cys Gln Ser
35      40      45
Tyr Cys Ile Thr Val Pro Ser Pro Asp Glu Lys Asn Ile Glu Glu Thr
50      55      60
Thr Lys Cys Cys Leu Pro Pro Ala Pro Arg Ala Arg Ala Pro Lys Ala
65      70      75      80
Asp Thr Glu Lys Tyr Thr Val Cys Met Asn Glu Cys Ile Ala Asp Asn
85      90      95
Tyr Trp Lys Ser Val Asp Gly Thr Pro Arg Gly Thr Asp Val Pro Asp
100     105     110
Val Lys Ser Lys Ala Ser Glu Ala Ala Ser Ser Ala Ala Glu Lys Ala
115     120     125
Thr Ala Thr Gly Thr Ala Ala Glu Ser Asp Ala Thr Ala Thr Gly Ala
130     135     140
Ser Ala Thr Glu Ser Glu Ser Gly Ser Asp Ser Ser Ser Glu Glu Thr
145     150     155     160
Gly Ser Ala Ser Gly Thr Ala Thr Gly Thr Ala Ala Glu Val Ser Glu
165     170     175
Thr Gly Asn Ala Ala Ser Ser Leu Val Gly Gly Val Ser Phe Leu Gly
180     185     190
Leu Val Ala Ala Ile Phe Ala Leu
195     200

```

<210> 3
 <211> 581
 <212> PRT
 <213> Fusarium

<400> 3

```

Met Leu Thr Gln Val Leu Tyr Gly Leu Val Ala Ser Ala Leu Trp Gln
1      5      10      15
Gly Gln Val Val Ala Ser Pro Ser Lys Asp Asn Ser Leu Glu Arg Phe
20      25      30
Ile Asp Lys Gln Ala Asp Ile Ser Ile Lys Gly Val Leu Ala Asn Ile
35      40      45
Gly Ala Asp Gly Lys Arg Ala Gln Gly Ala Ala Pro Gly Ala Val Val
50      55      60
Ala Ser Pro Ser Lys Glu Asp Pro Asp Tyr Trp Tyr Thr Trp Thr Arg
65      70      75      80
Asp Ser Ala Leu Thr Tyr Lys Val Leu Val Glu Arg Phe Ile His Gly

```

- 4 -

Asp Asp Glu Trp Arg
580

565

570

575

<210> 4
<211> 4047
<212> DNA
<213> Fusarium

<400> 4

aattagagag	gttagggatt	tcacatggcc	accaatggga	aggaggcaac	catctgcacg	60
agcccaccaa	gtcatctcct	caaactgtgc	tgcgactaag	aatttgattc	cggttctggc	120
ctggcctttg	tatcagctag	gtcattctcg	actaccggag	gccaggctga	agcagtcagt	180
cacgcattgt	cactttatcg	gtcctgtcct	catacggata	cactaggcgt	caatgggctt	240
caaacggaga	tccagagatc	tcatgaagag	catcgacgat	aaagtgagtg	gttggggata	300
ctgtgcggtg	ccgaccccag	cggcagccag	gttccaccct	tgattacatg	gttgaaaagt	360
ggcgttactg	ggcgagatca	aatttggtcat	gtatgttcgt	ccaatgacgc	gagctctcca	420
tgttgctgcg	agggtcagga	acggaccagc	atgggatcag	tgagggtgaaa	tccaaccgag	480
ggagagcgag	atctttgtgc	tcatatccat	gctgccatgc	tacgtgccga	acaggccaga	540
tggcgttcaa	ctcagtcgac	caggtccgat	gaacgcggag	cggtgacgag	atcgaagctt	600
catctatcgc	ttacgggggtt	atgttccact	ttccattaac	gtttgcgagt	tgctgtttga	660
gagccatgtc	gaaagcatgg	accgtgtcac	atctttcaag	gtaaatctgg	aggtgggaag	720
aagaattgcg	aggaacagga	tgggaggata	gcaggctgac	gcggaaagct	aggtagctac	780
ctggctgatt	actggctaaa	gctggagagc	aactaggtaa	tatcaggcaa	agagctccaa	840
gagctattgg	gaggctggct	gattgtctct	ggctgagacg	caggaggaag	ggttaaaatg	900
gccggcaggc	caagaagggg	ctgcaaaaaca	cggagtggat	ggtggggcct	cccacatacg	960
ggattcgggc	tgcggatcta	acctcaattt	ggcaagaggt	aaataggacg	acatgcaggc	1020
cccctgacat	gtaaacaaga	caagtggtaa	acaagccatc	aacatcaaca	agagcgaaca	1080
atcgacacac	ccatgggggt	gagatatggt	agtaaggcag	agagagatca	gggcagcata	1140
cgtgggaaag	ggctgggcaa	gaaaggacac	aacggatcaa	cagaacgcag	cgctaccgag	1200
ggagcaacac	aagtacagta	accgctcaca	gaggcacaac	tcgtccaatc	ctgcccccg	1260
cttcaaaagc	ccagtttcgt	tctgagtcct	gtccgggtccc	tcttctcctc	ctactccctc	1320
caattatcgc	catccacatc	gacatcgtca	attcacaacc	tcaccacagc	aagaagaaaa	1380
gaacgactga	aggccttcgc	tcgccatcac	ccgattcttt	tccattctct	tcgacttttg	1440
tttcgtagga	acaagagcca	gagaacttct	tgtcatcctt	tcgaatttcg	gaagggtgta	1500
tgagaagctt	ctctcgcgcc	agcaaaaagtc	gcaaactctgg	actttgaggc	acgcgtcccc	1560
gttcccttca	gcatcttccc	atcgacatat	cgggaatccg	aatcccacac	acagaccgtt	1620
accgaaaaca	agatacacga	agaggttgag	atcaaaccct	aacagcccga	agccggacgg	1680
gaagggtgaaa	tatcttctgt	ctccgtcacc	gccgaacagg	tccctcctcc	tcgtcaagag	1740
caagagttta	tcgaagaaga	ggtccatatt	acgcgtgaag	aagaacatta	ccaccgtccc	1800
ggtgtccaaa	aattcgagca	cgaagacttt	actatccgtg	aagactcccg	acggtacgtt	1860
cgattttaca	tttcctttca	tctccattta	ggtcgcattc	ttttcgttac	ttttttggtc	1920
aattacacgg	gggatacgat	tttcccacgg	tcggagaaag	ccctgcttgc	tctctatgcc	1980
taggtctgta	ttctctcatc	cctctgcgct	gatctggcca	tggagacgtg	tgagaacaag	2040
actacaattc	atcacatcat	ttttcgctag	gcgaaagcaa	ttaccgttgt	ccccgacctt	2100
ctcccaacca	tcagttttca	ctttcccttt	tcttggtctg	gcttgccctg	accattaccc	2160
accgcgcacg	gagcgcttca	gtccccagcc	atcccattct	cacatcactt	ctcatatcct	2220
ctcttcacac	gcctcacaca	cccacccctt	gcatgctacc	atgccaacc	acttcagctt	2280
ggctggatac	ccaatttgct	ttgcttcttc	cccggctcac	tagcgctctc	aagcctgctg	2340
gcctgagcaa	ggcgggtggag	ctatctcagg	ggcgcgcgcc	tcccgttgcc	atatgatacg	2400
caaacgactt	actatagaca	tccatcagct	aaccagaca	aatctagacc	tcaacctccc	2460
tctcaatacc	aaccttccca	gtaccaccaa	ccttcccact	accaaccacc	tcccaaattc	2520
caaactttct	acactcacgt	agagatcgac	accacccgtc	atccctacta	ctccaccccc	2580
attgatctcg	ctgaacgtga	ataccgccag	cgttaccgcc	ctgcccgaag	tttttccaca	2640
gaagaccctt	cttcccactc	tcatcctcac	taccaacctc	aagacaactt	caaagccaac	2700
aactacaccg	ttgaaggccg	accgcgtccc	caattccatt	cctctgagaa	gactgaaatc	2760
aacaagttta	ctggttgacga	acactcctct	cgccctcagt	acaaccacac	cgagaagacc	2820
gaattcaaca	actacactgt	tgacagccga	tcttcccgtc	ctcaatacaa	cacctgtgag	2880
aagactgaga	tcaacaattt	cactgttgac	gcccgtctct	cccagccacg	gtaccgcgac	2940
accaagacaa	ctcaagtcaa	cagctacgcc	ggtgacaagc	ccgtttctcg	tccatcttac	3000

aagaaggacg	tgagatttac	tgaacaaacc	gtcgaagctt	caaagtccga	caagtccaag	3060
atgggttact	acgacgacga	gggtaagtga	aatctgtcac	ccagcgagcg	ccatcaagct	3120
ctctattcgt	gacgcaattc	aagctaacc	agtcaccagg	ttctttccgc	aacggcggca	3180
tccacaagct	cggtgacaag	tcccgcgaca	ttgagggtga	cattcgcgag	acttctcgtc	3240
ctgccaatga	ctgcgctccc	aacaccgtca	gcatccccctg	ccaccacatc	cgtctgggtg	3300
atttccctcat	gctccagggc	cgccccctgcc	aggtcacccg	catctccacc	tcctctgcca	3360
ctggccagta	ccgctacctt	gggtgcgacc	tcttcaccaa	gcagcttcat	gaggagtctt	3420
ctttcatctc	caaccctgcc	cccagcgttg	tcgttcagtc	catgctcggc	cctgtcttca	3480
agcagtaccg	tgtcctcgat	atgcaggagg	gtcagatcgt	tgccatgacc	gagactggcg	3540
acgtcaagca	gggtctccct	gtcattgacc	agtccaacct	ctactctcgc	ctccacaacg	3600
ctttcgagtc	cggtcgtggc	tctgttcgcg	tcctcgtcct	caacgacggg	ggccgtgagc	3660
ttgccgttga	catgaaggtc	atccacggct	ctcgcctgta	agcgtgttca	actgttttct	3720
gaattcgggc	agccgcttgc	aatgcgactt	cttcccaatg	tttaattgag	tgaagggaca	3780
gcactaccag	tctcacctca	actgtgggga	gcgggtctgg	gctgtctcta	atcttacctg	3840
tacaatgtca	agtttcatag	gggacctgtt	gtgtcaagat	ggttcgagtt	ttgttttgtgt	3900
caagattgga	taaatgatat	tggctagctg	gaaatactgg	agtcttttgt	gtagatggga	3960
gagttctgta	catgaactat	agtaattgac	aattgattcc	gcatctactt	agcttttcat	4020
tggtgctcta	tgcccaacat	gtgaatt				4047

<210> 5

<211> 2517

<212> DNA

<213> Fusarium

<400> 5

aattactact	gtgatgtgat	cacacctaac	taaataccta	actcaccoga	tggatcgaca	60
aggaaatctc	acgcccttgt	cgagtctcct	ctttcgtctg	tctcctgggc	tcgctactgt	120
ccgattgtaa	ctctcgtctc	ccaacttgtt	caactcta	aagtgggtggc	acaacgtgaa	180
gatgtattgt	tgtgtgaggc	gggggggtgc	gtggcattac	caaagagacc	aaaagtcctc	240
ctatgtcgat	ttgatgggtg	tgcgttgcca	tgatacggga	ccccgaatat	gttgatgca	300
tcatgcgtac	agaaagctac	tgttcaaaac	gaacggcaaa	gcggattgat	caaccctgta	360
aagaccatgg	gtctctctca	gtccacaatc	ttctcttctc	gatcaaattt	atggatccaa	420
gcggccacaa	ttctagcgcc	atcatgggtc	cctttcctct	tttcgctcac	cccatgttcc	480
ctgtcccacc	tcattcagtg	gacctgatgg	atccctatcc	cccgatgagc	cgggggggtgc	540
agccttggcg	ctctcttctt	gttagtgtga	cctactgttg	atttcactca	gcagtcctag	600
agtccattta	gttgggctcg	gggtgatggg	gtctgagact	ttgcttcttg	cctgggtcttg	660
tctagctcga	atctgtgggt	tgcctggcct	ggcctggcct	gacctgacct	gaggggggtg	720
cccctttgct	ctgttctgca	tatgttgcta	ttagctacct	actcgagaat	tcataaaagg	780
actgtccagc	cccgctctct	actgacttct	ttcctttccc	tcttcaccct	cgttgtcata	840
tcaaactctgt	cactcgttag	accagactac	cattcccact	ttcgctttta	aactacttta	900
ctcaactaat	tctaatacca	actccaaaaa	ccatcaacat	gcgtttcaca	tcaatcctcg	960
ctgccggcgc	tttcgccacc	atggccgctg	cccagagcaa	gaccgtctcc	ctcgaccctg	1020
ctcagcagtc	tcaggccgac	tgcctctccg	actgtgagcc	tggcgatgtc	aagtgccagt	1080
cttactgcat	cactgtatgt	tacaacaacg	attcccctgt	catgtgtaga	aaactaacia	1140
tcccaatagg	ttccctctcc	tgacgagaag	aacatcgagg	aaaccaccaa	gtgttggttg	1200
ccgcctgccc	caagggcaag	ggctccgaag	gccgacactg	agaagtacac	cgtttgcatg	1260
aacgagtgtg	tcgccgacaa	ctactggaag	tccgttgatg	gtaccccccg	tggcaccgac	1320
gtccccgatg	tcaagagcaa	ggcctccgag	gctgcctcct	ccgctgctga	gaaggccacc	1380
gccaccggta	ctgctgctga	gtctgatgct	accgccactg	gtgcctccgc	tactgagtc	1440
gagtcgggct	ccgactccag	ctccgaggag	accggctctg	cctctggcac	tgccactggg	1500
accgctgctg	aggtctccga	gactggtaac	gccgcctctt	ccctcggttg	tggtgtctcc	1560
ttcctcggtc	tcgttgccgc	tatcttcgct	ctgtaaattg	ggtttctctg	tttaggataa	1620
tctgatttgg	catgacggag	aaggatttaa	tgggttttat	tacagcggta	atgattggag	1680
tttggaattc	aagatgtgac	acgttggaca	gcatgataag	gcctacgggt	ctgatcaatt	1740
tcatggacaa	attttgtttt	tttgggta	catrtcgct	tcacatatgg	ctcggcatat	1800
gagcatgaat	acaatacctc	ttttttgctc	ctcaattcat	tccaatttct	tgtgatctca	1860
cagtgattca	acttacaagt	tgcggcgcca	ccactgaggt	cgtgtctgat	gtgggtcttc	1920
tgtttgtgat	tggctcatga	ttcccaatcg	gggtgttcaa	acgttagttt	gtaaacaagc	1980
gaaatgaggg	tcttaggatg	catgttcaaa	gcgcaaaacc	caattgaatt	caaatgttaa	2040
agaatcatcg	agaagagcga	gttactgagg	tgaatttgtg	ctttcaactg	tcaatacctc	2100


```

cctcagaaca aatgaattga attattattc acactcaatg cccaatattc taaacatggt 2160
cgttgtaaca gagttttaat tccttgacgc cacaatgttc cttggtaatt atcgcgcttg 2220
tcacatgaac tggctcctga acttaaactg tggtgaccca gcaactcgtt tatcaggctt 2280
agggtagctg tcatacaaca aacaaacttg tacaattgat gttattgatg aatcatgtat 2340
agaagagcac aattgattta aacacagata aactggtcga accgatttta tcaggttgtg 2400
tgaacatgca ttgccgaatc agaaaccaga gtaagactat ctacagttcc atgaagacaa 2460
ttcacagact gccagaaagc aagggtactgg aagcacgaga gacaaaatta ttgaatt 2517

```

<210> 6
 <211> 187
 <212> PRT
 <213> Fusarium

```

<400> 6
Met Gly Tyr Tyr Asp Asp Glu Gly Ser Phe Arg Asn Gly Gly Ile His
  1          5          10          15
Lys Leu Gly Asp Lys Ser Arg Asp Ile Glu Val Asp Ile Arg Glu Thr
          20          25          30
Ser Arg Pro Ala Asn Asp Cys Ala Pro Asn Thr Val Ser Ile Pro Cys
          35          40          45
His His Ile Arg Leu Gly Asp Phe Leu Met Leu Gln Gly Arg Pro Cys
          50          55          60
Gln Val Ile Arg Ile Ser Thr Ser Ser Ala Thr Gly Gln Tyr Arg Tyr
          65          70          75          80
Leu Gly Val Asp Leu Phe Thr Lys Gln Leu His Glu Glu Ser Ser Phe
          85          90          95
Ile Ser Asn Pro Ala Pro Ser Val Val Val Gln Ser Met Leu Gly Pro
          100          105          110
Val Phe Lys Gln Tyr Arg Val Leu Asp Met Gln Glu Gly Gln Ile Val
          115          120          125
Ala Met Thr Glu Thr Gly Asp Val Lys Gln Gly Leu Pro Val Ile Asp
          130          135          140
Gln Ser Asn Leu Tyr Ser Arg Leu His Asn Ala Phe Glu Ser Gly Arg
          145          150          155          160
Gly Ser Val Arg Val Leu Val Leu Asn Asp Gly Gly Arg Glu Leu Ala
          165          170          175
Val Asp Met Lys Val Ile His Gly Ser Arg Leu
          180          185

```

<210> 7
 <211> 30
 <212> DNA
 <213> Fusarium

```

<400> 7
gagctcgagg aattcttaca aaccttcaac

```

30

<210> 8
 <211> 47
 <212> DNA
 <213> Fusarium

```

<400> 8
ttaattaagg tacctgaatt taaatgggtga agagatagat atccaag

```

47

<210> 9
 <211> 51
 <212> DNA
 <213> Fusarium

<400> 9
tcaccatttta aattcaggta ccttaattaa attccttggt ggaagcgtcg a 51

<210> 10
<211> 42
<212> DNA
<213> Fusarium

<400> 10
tggatatgcat aagcttgaat tcaggtaaac aagatataat tt 42

<210> 11
<211> 35
<212> DNA
<213> Fusarium

<400> 11
cagtgaattg gcctcgatgg ccgcggccgc gaatt 35

<210> 12
<211> 35
<212> DNA
<213> Fusarium

<400> 12
aattcgcggc cgcggccatc gaggccaatt cactg 35

<210> 13
<211> 34
<212> DNA
<213> Fusarium

<400> 13
cacgaaggaa agacgatggc tttcacggtg tctg 34

<210> 14
<211> 34
<212> DNA
<213> Fusarium

<400> 14
cagacaccgt gaaagccatc gtctttcctt cgtg 34

<210> 15
<211> 46
<212> DNA
<213> Fusarium

<400> 15
ctatctcttc accatggtag ctttaattaa taccttggtg gaagcg 46

<210> 16
<211> 46
<212> DNA
<213> Fusarium

<400> 16
cgcttccaac aaggtattta attaaggtag catggtgaag agatag 46

<210> 17

<211> 30
 <212> DNA
 <213> Fusarium

<400> 1
 attttaaattt tgaagagctc ccttggtgctg 30

<210> 18
 <211> 24
 <212> DNA
 <213> Fusarium

<400> 18
 ttaatttaatt agatcgacc cagccgcgc 29

<210> 19
 <211> 41
 <212> DNA
 <213> Fusarium

<400> 19
 ataagaattgt gaaagctagt ttaaacttac aaaccttcaa cagtg 45

<210> 20
 <211> 19
 <212> DNA
 <213> Fusarium

<400> 20
 tagcatctat ctccgtctt 19

<210> 21
 <211> 19
 <212> DNA
 <213> Fusarium

<400> 21
 gtgtgcagtg acccagaat 19

<210> 22
 <211> 42
 <212> DNA
 <213> Fusarium

<400> 22
 gattgggtcc ctacgtagtt aacactatag gccatcgttt ac 42

<210> 23
 <211> 28
 <212> DNA
 <213> Fusarium

<400> 23
 atttaaatat ggtttcttcg gcattcgc 28

<210> 24
 <211> 28
 <212> DNA
 <213> Fusarium

<400> 24
ttaattaact attccgacgg aacaaagc 28

<210> 25
<211> 44
<212> DNA
<213> Fusarium

<400> 25
ctcttgata tctatctctt caccatgggt tcttcggcat tcgc 44

<210> 26
<211> 43
<212> DNA
<213> Fusarium

<400> 26
gcgaatgccg aagaaaccat ggtgaagagt agatatccaa gag 43

<210> 27
<211> 30
<212> DNA
<213> Fusarium

<400> 27
gaatgacttg gttgacgcgt caccagtcac 30

<210> 28
<211> 26
<212> DNA
<213> Fusarium

<400> 28
tctagcccag aatactggat caaatc 26

<210> 29
<211> 39
<212> DNA
<213> Fusarium

<400> 29
cttaactttg acttgaaaaa catatctgac atttgctcc 39

<210> 30
<211> 59
<212> DNA
<213> Fusarium

<400> 30
ggacggcctt ggctagccct ccgtgcggcc gccggccggt ctgcaggat ctgtttaac 59

<210> 31
<211> 32
<212> DNA
<213> Fusarium

<400> 31
atatcgtgaa gatatgcggc attgatgcca cc 32

<210> 32

<211> 35

<212> DNA

<213> Fusarium

<400> 32

ggcggcaata accggccgaa cattccggat atccc

35

<210> 33

<211> 32

<212> DNA

<213> Fusarium

<400> 33

cactgctatc accaacaatgt ttactcaagt cc

32

<210> 34

<211> 32

<212> DNA

<213> Fusarium

<400> 34

ggacttgagt aaacatgttg gtgatagcag tg

32

<210> 35

<211> 29

<212> DNA

<213> Fusarium

<400> 35

gactcatgag gagctccctt gtgctgttc

29

<210> 36

<211> 34

<212> DNA

<213> Fusarium

<400> 36

tgattaatta acctaaagac atgtcccaat taac

34

<210> 37

<211> 25

<212> DNA

<213> Fusarium

<400> 37

gcatttaaata tactactgtg atgtg

25

<210> 38

<211> 25

<212> DNA

<213> Fusarium

<400> 38

gattgatgtg aaacacatgt tgatg

25

<210> 39

<211> 25

<212> DNA

<213> Fusarium

<400> 39
cgacccggga attagagagg ttagg

25

<210> 40
<211> 18
<212> 18A
<213> Fusion: 18

<400> 40
cgtatataaa atggaggact tgcggac

28

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 September 2000 (28.09.2000)

PCT

(10) International Publication Number
WO 00/56900 A3

(51) International Patent Classification⁷: C12N 15/63.
15/11, 15/80

(74) Agents: ZELSON, Steve, T. et al.: Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY 10174 (US).

(21) International Application Number: PCT/US00/07815

(22) International Filing Date: 22 March 2000 (22.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/274,449 22 March 1999 (22.03.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(71) Applicant: NOVO NORDISK BIOTECH, INC.
[US/US]: 1445 Drew Avenue, Davis, CA 95616-4880 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors: BERKA, Randy, M.: 3609 Modoc, Davis, CA 95616 (US). REY, Michael, W.: 605 Robin Place, Davis, CA 95616 (US). BROWN, Kimberly: 8322 Windswept Court, Elk Grove, CA 95758 (US). BROWN, Stephen, H.: 3708 Miwok Place, Davis, CA 95616 (US).

Published:
— with international search report

(88) Date of publication of the international search report:
31 January 2002

[Continued on next page]

(54) Title: PROMOTER SEQUENCES DERIVED FROM FUSARIUM VENENATUM AND USES THEREOF



(57) Abstract: The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first nucleic acid sequence encoding the polypeptide operably linked to a second nucleic acid sequence comprising a promoter foreign to the nucleic acid sequence, wherein the promoter comprises a sequence selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO. 1, nucleotides 1 to 938 of SEQ ID NO. 2, and nucleotides 1 to 3060 of SEQ ID NO. 3, and a subsequence thereof; and mutant, hybrid, and tandem promoters thereof; and (b) isolating the polypeptide from the cultivation medium. The present invention also relates to the isolated promoter sequences and to constructs, vectors, and fungal host cells comprising the promoter sequences operably linked to nucleic acid sequences encoding polypeptides.

WO 00/56900 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07815

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/63 C12N15/11 C12N15/80

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data, PAJ, STRAND, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 05474 A (UNIVERSITY OF LEEDS) 23 February 1995 (1995-02-23) cited in the application abstract page 2, line 9 -page 5, line 8 page 10, line 1 -page 11, line 8 page 12, line 30 -page 16, line 15 page 17, line 10 -page 18, line 22 page 19 -page 21; claims 8-27 page 23 -page 24; figure 1 --- -/--	52-56



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

31 January 2001

Date of mailing of the international search report

31 January 2001 (31.01.01)

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07815

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database, Heidelberg, FRG Emfun accession number AF001033 21 June 1997 HUNT, I.E. & BOWMAN, B.J.: "Neurospora crassa putative 20 kDa subunit of the V-ATPase gene, complete cds." XP002159031 the whole document	52-56
X	-& EMBL Database, Heidelberg, FRG Trembl accession number P87252 01 July 1997 HUNT, I.E. & BOWMAN, B.J.: "PUTATIVE 20 KDA SUBUNIT OF THE V-ATPASE. (Neurospora crassa)" XP002159032 cited in the application the whole document	52-56
A	EMBL Database, Heidelberg, FRG Swissprot accession number P56092 01 November 1997 NAKAZAWA, T.: "EPD1 PROTEIN PRECURSOR (ESSENTIAL FOR PSEUDOHYPHAL DEVELOPMENT). (Candida maltosa)" XP002159033 the whole document	52-56
A	WIEBE, M.G. ET AL.: "Appearance of morphological (colonial) mutants in glucose-limited, continuous flow cultures of Fusarium graminearum A3/5" MYCOLOGICAL RESEARCH, vol. 95, no. 11, 1991, pages 1284-1288, XP000197035 cited in the application abstract page 1286; table 1 page 1287; figure 2A	1-43, 45-51
A	WO 96 00787 A (NOVO NORDISK BIOTECH, INC.) 11 January 1996 (1996-01-11) cited in the application the whole document	1-43, 45-51
A	KIMURA, M. ET AL.: "Trichothecene 3-O-Acetyltransferase Protects Both the Producing Organism and Transformed Yeast from Related Mycotoxins" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 3, 16 January 1998 (1998-01-16), pages 1654-1661, XP002125091 the whole document	1-43, 45-51

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/07815

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 44
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210 .
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

R mark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-43, 45-51 completely

A method for producing a polypeptide, comprising: a) cultivating a fungal host cell in a medium conducive for the production of said polypeptide, wherein the fungal host cell comprises a first nucleic acid sequence encoding said polypeptide operably linked to a second nucleic acid sequence comprising a promoter foreign to the first nucleic acid sequence, wherein the promoter comprises a sequence selected from the group consisting of nucleotides 1 to 3949 of SEQ ID NO: 1 (corresponds to SEQ ID NO: 1 in the sequence listing), nucleotides 1 to 938 of SEQ ID NO: 2 (corresponds to SEQ ID NO: 5 in the sequence listing), and nucleotides 1 to 3060 of SEQ ID NO: 3 (corresponds to SEQ ID NO: 4 in the sequence listing), and subsequences thereof, and mutant, hybrid, and tandem promoters thereof, and b) isolating said polypeptide from the cultivation medium, an isolated promoter sequence comprising a nucleic acid sequence selected from the group consisting of said nucleotides of SEQ ID NO: 1, 2 and 3, and subsequences thereof, and mutant, hybrid, and tandem promoters thereof, an isolated promoter sequence comprising a nucleic acid sequence having at least one mutation in the sequence of said nucleotides of SEQ ID NO: 1, 2 and 3, or a subsequence thereof, a nucleic acid construct comprising a nucleic acid sequence encoding a polypeptide operably linked to said promoter, a recombinant expression vector and a recombinant host cell comprising said nucleic acid construct, a method for producing a polypeptide comprising a) cultivating a homologously recombinant cell, having incorporated therein a new transcription unit comprising said promoter, an exon, and / or splice donor site operably linked to a second exon of an endogenous nucleic acid sequence encoding said polypeptide, under conditions conducive for the production of said polypeptide, and b) recovering said polypeptide and methods for obtaining a mutant promoter;

2. Claims: 52-56 partially

An isolated nucleic acid sequence, selected from the group consisting of: a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 65% identity with amino acids 22 to 581 of SEQ ID NO: 4 (corresponds to SEQ ID NO: 3 in the sequence listing), b) a nucleic acid sequence having at least 65% homology with nucleotides 4013 to 5743 of SEQ ID NO: 1 (corresponds to SEQ ID NO: 1 in the sequence listing), c) a nucleic acid sequence which hybridizes under very low, low, medium, medium-high, high, or very high stringency conditions with (i) nucleotides 4013 to 5743 of SEQ ID NO: 1, (ii) the cDNA sequence contained in nucleotides 4013 to 5743 of SEQ ID NO:

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii) or (iii), d) a nucleic acid sequence encoding a variant of the polypeptide having an amino acid sequence of SEQ ID NO: 4 comprising a substitution, deletion, and / or insertion of one or more amino acids, e) an allelic variant of a), b), or c), and f) a subsequence of a), b), c), or e), a polypeptide encoded by said nucleic acid sequence, a nucleic acid construct comprising said nucleic acid sequence operably linked to one or more control sequences which direct the production of said polypeptide in a suitable expression host, a recombinant expression vector comprising said nucleic acid construct, a promoter, and transcriptional and translational stop signals and a recombinant host cell comprising said nucleic acid construct;

3. Claims: 52-56 partially

Idem as subject 2 but limited to the amino acids 19 to 200 of SEQ ID NO: 5 (corresponds to SEQ ID NO: 2 in the sequence listing) and the nucleotides 993 to 1593 of SEQ ID NO: 2 (corresponds to SEQ ID NO: 5 in the sequence listing);

4. Claims: 52-56 partially

Idem as subject 2 but limited to the amino acids 1 to 187 of SEQ ID NO: 6 (corresponds to SEQ ID NO: 6 in the sequence listing) and the nucleotides 3061 to 3678 of SEQ ID NO: 3 (corresponds to SEQ ID NO: 4 in the sequence listing).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 44

Present claim 44 relates to a promoter sequence characterized by the desirable property "having the same promoter activity as the promoter sequence of any of claims 33-43". The claim covers all promoter sequences having this characteristic or property, whereas no support within the meaning of Article 6 PCT and no disclosure within the meaning of Article 5 PCT of such a promoter sequence is provided by the application. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the promoter sequence by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for the promoter sequences claimed in claim 44.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/07815

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505474 A	23-02-1995	AU 687852 B	05-03-1998
		AU 7388994 A	14-03-1995
		CA 2169377 A	23-02-1995
		EP 0714445 A	05-06-1996
		JP 9507742 T	12-08-1997
		US 5834191 A	10-11-1998
WO 9600787 A	11-01-1996	AU 2705895 A	25-01-1996
		CN 1151762 A	11-06-1997
		EP 0777737 A	11-06-1997
		FI 965220 A	25-02-1997
		JP 10500024 T	06-01-1998
		US 6060305 A	09-05-2000
		US 5837847 A	17-11-1998

